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Abbreviations 
 
amu: atomic mass unit 
CID: collision induced dissociation 
CNS: central nervous system 
CSF: cerebrospinal fluid  
EST: expressed sequence tags 
ESI: electrospray ionization  
ET: extended protein 
FT: Fourier transform 
FT-ICR: Fourier transform ion cyclotron resonance 
FWHM: full width of the peak at half of its maximum height 
GC: gas chromatography 
HCD: high energy C-trap dissociation 
HPLC: high performance liquid chromatography 
ICR: ion cyclotron resonance 
LC-MS: liquid chromatography mass spectrometry 
LTQ: linear trap quadrupole 
m/z: mass-over-charge ratio 
MALDI: matrix-assisted laser desorption ionisation 
MS: mass spectrometry 
MS/MS: tandem mass spectrometry fragmentation 
NanoLC: nanoflow liquid chromatography 
NanoES: nanoelectrospray 
ppm: part per million 
PTM: post-translational modification 
Q-TOF: quadrupole time of flight  
RF: radio frequency 
RP: reverse phase 
RT: retention time 
TOF: time of flight 
UV: ultraviolet light wavelength 
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Summary 
 
The recent achievements of proteomics are mainly due to  the developments in the high accuracy 
and resolution mass spectrometry. Protein identification by conventional proteomics “shotgun” 
approach involves enzymatic cleavage and consequent identification of the resulting peptide 
products. Typically, several peptides belonging to the same unique protein are produced by this 
process and, considering the improved sensitivity and separation abilities of the contemporary 
LC-MS instrumentation, it is feasible to identify a known protein with at least two unique 
peptides by submitting a query to a protein database.  In order to be time efficient, a typical LC-
MS run includes high accuracy identification of the precursor peptide mass during the MS scan 
event and significantly less accurate but fast MS/MS peptide fragmentation signature profiling. 
This scheme generally satisfies very stringent protein identification requirements.  However, 
identification of endogenous peptides such as neuropeptides, for example, often must rely on one 
peptide only and, hence, has to be much more accurate in order to provide the needed level of 
confidence. Likewise, the MS/MS data have to be very accurate for identification and 
characterization of novel post-translational modifications. Furthermore, de-novo sequencing of 
unknown proteins not present in protein databases frequently relies initially on the discovery of 
only one peptide which provides the basis for the following characterization of the unknown 
protein. For the above-mentioned cases the availability of high accuracy data in both MS and 
MS/MS modes is of the utmost importance. In my work I utilized high accuracy mass 
spectrometry for discovery of novel extended forms of nuclear proteins and underlying mRNA 
editing events, and, also, for characterization of the human cerebrospinal fluid peptidome and 
proteome. 
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“Tout progrès scientific est un progrès de method.” 
 
“All scientific progress is progress of a method.” 
 
                                                                     René Descartes 
 
 
 
Introduction 
 
 
The extraordinary achievements of current proteomics are based largely on successful 
developments in the fields of mass spectrometry (MS) and separation science.  Once joined, the 
two disciplines provided a powerful tool to investigate the protein universe. 
 
Mass spectrometry 
 
Mass spectrometry is the science of determining mass-to-charge ratios (m/z) of ionized 
molecules. In 1897 Sir Joseph John Thomson, a British physicist, in a series of experiments with 
cathode rays discovered the existence of the electron and determined its mass to charge ratio m/z 
(1). He was awarded the Nobel Prize in physics in 1906 and is considered a founder of the field 
of mass spectrometry. It took more than half a century of research and development before a first 
commercial mass spectrometer appeared, and almost a century to fully (or almost fully) seize the 
analytical potential of the MS instruments.  This development has gone in many directions – with 
different instrument designs using different physical principles. However, the essence of any 
mass spectrometer is the same – to determine the m/z of an introduced ion. William Stephens of 
the University of Pennsylvania presented the idea of the time-of-flight (TOF) mass analyzer at 
the 1946 American Physical Society Meeting in Cambridge. His concept was to accelerate all 
ions to the same kinetic energy. Thus an accelerated ion would have the same kinetic energy as 
any other ion (provided they had the same charge), with the velocity depending solely on m/z 
(2). Wiley and McLaren of Bendix Corporation in Detroit introduced a TOF focusing scheme 
that improved mass resolution by correcting energy distributions of the ions (3). As the result, 
Bendix was the first to commercialize TOF instruments in the 1950s. In 1973 Boris Mamyrin, a 
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Russian scientist who worked at the Leningrad Physico-Technical Institute, described the 
reflectron and the energy compensating mirror system which corrected for the effects of the 
kinetic energy distribution of the ions in the TOF tube. This invention resulted in a dramatic 
increase of TOF resolution (4). Needless to say, the 1970s were also the years when the 
affordable fast timing electronics became available which was crucial for the further 
development of the time-of-flight field in order to handle the huge data flow. In 1953 German 
physicists Wolfgang Paul who worked at Bonn University and Helmut Steinwedel at University 
of Wurzburg registered a patent describing the quadrupole mass analyzer (5). They showed that 
the static and radio frequency (RF) quadrupole oscillating electric fields can be used to act as an 
m/z separator. This discovery led to the development and commercialization of triple quadrupole 
mass analyzers and 3D ion trapping instruments. The first three-dimensional versions of the 
device now known as a Paul trap (or ionenkäfig, the “ion cage”, as Paul liked to call it) were 
developed by Wolfgang Paul and Hans Dehmelt (University of Washington) and allowed to 
detect and measure the ions while stored. Later developments added the ability of mass-selective 
storage and ejection to the ion-trap resulting in the production of a reliable commercial 
instrument by George Stafford at the Finnigan company (6). For the “development of the ion trap 
technique” Paul and Dehmelt were awarded Nobel Prize in Physics in 1989. In 1932 Ernest 
Lawrence described a cyclotron principle and its application to high energy physics which 
brought him a Nobel Prize in Physics in 1939 (7). More than forty years afterwards, in 1974, 
Fourier Transform Ion Cyclotron Resonance (FT-ICR) mass spectrometry was introduced by 
Alan Marshall and Mel Comisarow (8). In this method the ions present in the cyclotron cell are 
excited by broadband RF. In a strong fixed magnetic field each ion of a given mass will have its 
characteristic cyclotron frequency. The circulating tight packets of such ions induce image 
currents which are decoded by Fourier Transform (FT) analysis. Even though their maintenance 
is cumbersome because of the need for constant supply of liquid nitrogen and helium to keep the 
superconductive magnets going, FT-ICR mass spectrometers are the most accurate mass 
measuring instruments. Different mass analyzers can be coupled together in order to use their 
properties to the fullest potential – current mass spectrometry is dominated by such hybrid 
instruments. The successful hybrid quadrupole-TOF (Q-TOF) instrument, for example, was 
developed in the late 1990s at MDS SCIEX, Concord, Canada and combined the guiding and 
isolating properties of a quadrupole mass filter with the high accuracy of the  TOF detection 
6
 
 
analyzer (9). It took more than 80 years since the original discovery of orbital trapping by 
Kingdon in 1923 (10) before the commercial hybrid linear triple quadrupole (LTQ)-Orbitrap 
instrument by Thermo Finnigan hit the market. This hybrid instrument combines the guiding, 
trapping and detection properties of the linear quadrupole trap with the high accuracy m/z 
detection ability of the Orbitrap - the work by the Russian physicist Alexander Makarov at HD 
Technologies Inc., Manchester, UK built the foundation for the successful entry of this machine 
into the proteomics world. Using Kingdon‟s concept he created a high accuracy and high 
resolution instrument, the orbitrap, in which the ions could be trapped in the absence of any 
magnetic or radio frequency field, and ion stability is achieved only due to ions orbiting around 
an axial electrode. The oscillations of the ions are revealed using image current detection and are 
decoded by Fourier Transformation (11). The accuracy and resolving power of the orbitrap is 
comparable with that of FT-ICR instruments but without the need for expensive maintenance. 
 
Generating ions 
 
Availability of instruments that allowed mass determination of molecules was attractive for 
biologists. However, in order to determine the m/z of a molecule this molecule has to be ionized 
and introduced into the gas phase. This requirement was less of a challenge for small organic 
molecules, which were forced into the gas phase by heating leading to vaporization and 
subsequently converted to ions by electron or chemical ionization (12, 13). Both methods 
resulted in post-source fragmentation of the generated ions, with the lower energy chemical 
ionization being somewhat less destructive of the generated ions. For obvious reasons, proteins 
and polypeptides could not be introduced into the gas-phase by such a harsh treatment. The 
question of finding the proper ionization method was of the utmost importance for biological 
mass spectrometrists. The solutions appeared with the publications of John Fenn‟s group at Yale 
University, USA (14, 15) which ignited the development of the electrospray ionization (ESI) 
field, and Michael Karas and Franz Hillenkamp at Frankfurt University, Germany (16), and 
Koichi Tanaka at Shimadzu Inc., Japan (17) which resulted in the development of the matrix-
assisted laser desorption ionization (MALDI) methods. TMALDI and ESI provided “soft”, non-
destructive ways of ionization for biomolecules and, eventually, lead to the establishment of 
7
 
 
mass spectrometry-based proteomics. These achievements were recognized by the awarding of 
the 2002 Nobel Prize in Chemistry to John Fenn and Koichi Tanaka. 
 
MALDI - matrix-assisted laser desorption ionisation 
 
In MALDI the analyte is mixed with an excess of matrix molecules. Upon drying, the analyte 
molecules are incorporated into the matrix crystals. The matrix absorbs energy at the wavelength 
of a laser and transfers it into the analyte. This causes the analyte to vaporize and form ions 
(Figure 1). MALDI ion sources are typically combined with TOF mass spectrometers. In 1989 
Ronald Beavis and Brian Chait reported the discovery of suitable UV matrices for polypeptide 
characterization by MALDI (18). The UV-excitable matrices were based on cinnamic acid and, 
mostly, have not changed ever since. Reliable UV lasers for MALDI became available in the late 
1980s. These developments favored general acceptance of MALDI-TOF instrumentation in 
biological research. The MALDI process produces predominantly singly-charged (1+) ions 
which are not fragmented easily by the low energy collision induced dissociation (CID) process 
employed in many contemporary mass spectrometers. If one has to only determine a mass of a 
protein, having a 1+ ion is of advantage because no peak deconvolution post-processing is 
involved – in many cases deconvolution of the multiply charged envelopes of large proteins is a 
very complicated, if not close to impossible, process. Furthermore, a pure protein entity or 
simple protein mixture can be identified after digestion with a specific protease of choice. The 
resultant peptides are analyzed by a MALDI-TOF instrument and their corresponding masses 
compared to a database containing information about the peptide masses calculated for each 
protein sequence. This identification method is called “peptide mass fingerprinting”.  
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Figure 1.    MALDI (matrix-assisted laser desorption ionization) process – analyte is vaporized  
                   together with matrix molecules forming predominantly 1+ ions. 
 
However, if one needs to analyze a complex protein mixture, as is usually the case in biology, or 
the need arises to further characterize the ionized polypeptide by finding out its detailed primary 
structure, the peptide ions must be isolated and fragmented. In such a case, multiply charged ions 
are advantageous.  
 
   
ESI – electrospray ionization 
 
The ESI process transforms solubilized analyte molecules into gaseous ions at atmospheric 
pressure. The electric field is applied between the spraying capillary containing the analyte and 
the entry point of a mass spectrometer. Ions accumulate at the liquid surface of the capillary 
through which liquid is passed (Figure 2). When the surface tension in the cone is exceeded, a 
conical shape known as „Taylor cone‟ is formed charged micro-droplets with a diameter less than 
or equal 1-10 µm are produced. The solvent quickly evaporates after the droplets are formed, 
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electric surface charge density of the droplet increases and, finally, the droplet bursts releasing 
the ionized analyte species. ESI allows formation of multiply-charged ions, which makes 
fragmentation of the ions significantly easier compared with the 1+ species. As a result, if one 
needs to find an internal signature of an ion (ionized peptide) one isolates the ion, fragments it 
and performs interpretation of the resulting fragmentation pattern. ESI is easily interfaced with 
liquid chromatography-based instrumentation therefore allowing on-line separation of complex 
samples. Due to the multiple-charged nature of the ions generated by ESMS, their m/z ratios are 
“collapsed” relative to their nominal masses allowing the use of simple (with narrow m/z range 
of detection) and relatively inexpensive quadrupole instruments. 
 
 
 
 
 
                               
 
 
 
Figure 2.  Electrospray ionization process – analyte is transformed into a mist of charged 
droplets. 
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Assessing the limits of protein detection 
 
The early 1990s was the time when biological mass spectrometrists started to test the limits of 
protein detection. Mark Emmett and Richard Caprioli demonstrated low attomole detection 
limits with electrospray (19). They reported the development of the micro-electrospray ion 
source which significantly increased the sensitivity of peptide identification by ESI. The ion 
source was modified to accommodate a capillary needle. The needle was coated with C18 
chromatographic packing material and the liquid flow rate was in the range of 500 nl/min.  The 
authors noted the capability of their spraying device to be positioned closer to the MS analyzer 
entry point, and suggested that the decreased distance from the mass spectrometer nozzle and 
low flow rate gives a spray pattern of narrow dispersion which allows more analyte to be drawn 
into the analyzer leading to better sensitivity. In 1994 Ole Vorm and Matthias Mann 
demonstrated the attomole detection capabilities of  MALDI (20). They described a sample 
preparation procedure in which matrix and sample handling are completely decoupled - first, a 
drop of matrix is deposited onto the MALDI plate, second, a drop of analyte solution is deposited 
onto the layer of the matrix microcrystalls. The simple sample preparation procedure leads to 
improvement in sensitivity, with peptides routinely analyzed at the attomole range. The same 
year, Matthias Wilm and Matthias Mann reported development of the nanoelectrospray ion 
source (nanoES). The nanoES source employed pulled capillaries with 1-2 µm spraying orifice 
and about 20 nl/min flow rate which lead to very small droplet sizes and improved desolvation 
efficiency.  The sample is loaded directly into the spraying capillary. The nanoES flow is not 
forced by solvent pumps – it is driven by the electrospray process itself (21). In 1996 Andrej 
Shevchenko and Matthias Mann established the feasibility of the microcharacterization of silver-
stained proteins by MALDI and NanoES tandem mass spectrometry (22). They proved the 
compatibility of the highly sensitive silver-staining method with microanalytical protein 
characterization. The sample detection limit in this case was 10-100 times lower than that 
obtained with Coomassie staining. They also pointed out the advantage of NanoES MS/MS 
profiling over MALDI peptide mass fingerprinting when identifying less abundant protein 
components of complex protein mixtures – indeed, the identification of the low level proteins is 
often based only on few peptides which are “hiding” in the background of the peptide products 
of more abundant proteins. 
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Isotopic envelopes 
 
Most chemical elements exist as diverse masses in nature, the isotopes of the element. Proteins 
are composed of carbon (C), hydrogen (H), nitrogen (N), oxygen (O), sulfur (S) and phosphorus 
(P). The natural abundances of the corresponding isotopes are shown in Figure 3. 
 
                                             
  
Figure 3. Isotopic abundances of protein elemental components. 
 
About 1.11 % of the naturally occurring carbon 
13
C atoms are 1.0034 Da heavier than the C12 
atoms. This means that from a random set of 100 carbon atoms about 99% will have a mass of 
12.0000 Da and 1% will have a mass of 13.0034 Da. The larger the polypeptide mass, the higher 
the probability of C13 incorporation into this molecule and the more prominent the isotopic effect 
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(Figure 4). In fact, large polypeptides show inversion of the isotopic envelope when the first C12-
only monoisotopic peak is less intense than the adjacent C13-containing peaks (Figure 4C). 
Because it is a major building block of polypeptides and has distinct isotopic diversity, carbon 
has the most prominent effect on the polypeptide isotopic profile.  
 
   
 
Figure 4. Isotopic envelopes of singly-charged leucine (L)-containing peptides. 
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Accuracy and resolution 
 
The mass accuracy of a mass spectrometer is defined as the difference between the measured 
mass and its calculated value. Traditionally relative mass accuracy is reported and defined in 
parts per million (ppm) – the mass accuracy divided by a calculated value of the measured mass. 
High mass accuracy is directly related to the ability of a mass spectrometer to separate the 
adjacent peaks, to its resolution. The resolution can be calculated by dividing the m/z of a peak 
by its width at a certain height (m/z divided by Δm/z). A common definition of resolution is Full 
Width of the peak at Half of its Maximum height, abbreviated as 'FWHM', the Δm/z value in this 
case is taken at 50% of the peak height (Figure 5). The difference between the resolution of 
different instruments is enormous. An average quadrupole type instrument has a FWHM 
resolution of 2000 in the 400-800 m/z range (it is still common to use the “unit resolution” 
definition for the triple quadupole analyzers which refers to the ability of the instrument to 
separate each mass from the next integer mass), whereas advanced hybrid instruments offer 
resolution of up to 100 000 in this range and even more. For the purpose of identification the 
accuracy of a mass spectrometer is of the utmost importance – indeed, the more accurately one 
determines the masses of peptides and their fragments the better the probability of correct 
identification. The linear trap quadrupole instrument (LTQ), for example, has an accuracy of 
about 150 ppm at 700.0 m/z; the Quadrupole-TOF analyzer (Q-TOF) offers about 20-30 ppm 
accuracy at this m/z value, and the LTQ-Orbitrap achieves 0.5-1 ppm.  
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Figure 5.  Full Width of the peak at Half of its Maximum height (FWHM) resolution of (a) 4000 
and (b) 50000. 
 
 
Analyzing the ionized peptides 
 
It is important to stress that a mass spectrometer determines the mass-over-charge ratio and not 
the mass of the introduced ions. Most common proteomics experiments utilize positive 
ionization mode for peptides. The resulting charge of the peptide ion directly corresponds to the 
number of accepted protons (1+ means 1H+ accepted; 2+ means 2H+ accepted etc.). The 
isotopic nature of the ionized protonated peptides allows elucidating of their charge and, 
consequently, mass (Figure 6). For example, the mass difference of 0.5017 (1.0034/2) atomic 
units (amu) between the peaks of the isotopic envelope corresponds to the charge of 2. 
Multiplying the m/z value of the first, monoisotopic, peak of the envelope by its charge and 
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subtracting the mass of the corresponding accepted protons (1.0073 Da per 1H+) yields the 
experimental monoisotopic mass of the peptide. 
 
      
 
 
Figure 6. Charge profiles of the hypothetical MASSSPECTRA peptide. 
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Tryptic peptides and fragmentation 
 
In a typical proteomics experiment a protein mixture is digested by an enzyme thus creating a 
mixture of peptides. The most common protease is trypsin which cuts protein C-terminally at 
arginine (R) or lysine (K) residues and gives rise to peptides carrying at least one basic residue 
(except the C-terminal peptide of the protein). At pH 3, Asp- and Glu- are uncharged and any 
proteolytic peptide has the net charge of at least 2+ where one charge is located C-terminally at 
the basic residue and another charge is localized at the N-terminus.  
 
 
 
 
 
 
 
Figure 7. Typical tryptic peptide. 
 
 
 
The opposite location of the charges facilitates peptide fragmentation  at the amide bond in the  
most commonly used low energy collision induced dissociation (CID) process creating y and b 
ion series according to Roepstorff-Fohlmann-Biemann nomenclature (23).  
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Figure 8. Roepstorff-Fohlmann-Biemann nomenclature for low energy CID. The blue shape 
indicates the peptide bond that is fragmented, in this case giving rise to the b2 and y6 fragment 
ions. 
 
This convenient placement of the charges is typical of tryptic peptides generated by enzymatic 
digestion but it is not usual for endogenous peptides.  Their amino acid sequence does not follow 
strict rules - the basic residues, if any, are distributed over the sequence which makes the analysis 
of such molecules much more challenging than that of tryptic peptides.  In addition, functional 
endogenous peptides such as neuropeptides are often post-translationally modified. 
Modifications such as phosphorylation or glycosylation are very labile and their loss is often the 
predominant fragmentation channel, reducing CID fragmentation efficiency. 
 
NanoLC-MS 
 
Currently capillary columns are the most effective chromatographic separation devices available. 
The capillary column format results in a dramatic increase of the LC-MS sensitivity due to the 
concentration effect (Figure 9).  Capillary columns were originally introduced for gas 
chromatography (GC) by Marcel Golay of Perkin Elmer at the 1958 Symposium on Gas 
Chromatography (24) more than fifty years ago. He presented the separation of C8 hydrocarbons 
and the xylene isomers on a 50 m x 0.25 mm stainless steel diisodecyl phthalate coated column 
together with about 90 equations supporting his elegant concept. About a decade afterwards, the 
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idea of using capillary separations for liquid chromatography (LC) was clarified in publications 
of Horvath et al. (25) and Ishii (26). The field evolved in parallel with research and development 
in the area of the chromatographic stationary supports. The requirements of pharmaceutical 
chemistry have been the major driving force for the advancement of chromatographic techniques 
because the quality of pharmaceutical products is determined by the quality of their 
chromatographic analysis. The expansion of chemically bonded hydrophobic stationary phases 
which were named reverse phase (RP) packings in High Performance Liquid Chromatography 
(HPLC) began in 1970 when  Jack Kirkland of Du Pont de Nemours & Co, Delaware 
synthesized a hydrophobic bonded phase by coupling a poly-n-octadecylsiloxane to the surface 
of a pellicular matrix (27). Soon after, Ron Majors prepared bonded phases by the reaction of 
organotrichlorosilanes with microparticulate silicas (28). The challenge was to synthesize RP 
silicas to separate basic analytes with sufficiently symmetrical peak shape and reproducible 
retention coefficients. The problem was solved by manufacturing silicas with a reduced acidity 
and a high purity and appropriate n-alkyl functionality. Furthermore, many separations, 
especially peptide separations, were performed using acidic mobile phases and organic mobile 
phases at pH 2–3. This required RP packings with a high stability at acidic pH. Jack Kirkland 
and his team at Rockland Technologies, Delaware successfully developed a number of surface 
chemistries, including the introduction of steric protection of the siloxane bond that holds the 
bonded phase to the silica surface and bidentate bonded phases with two anchoring siloxane 
bonds (StableBond and Extend, respectively). The introduction of spherical particles improved 
packing stability of the columns. Further reduction of the diameter of the stationary phase 
particles from initially 10 – 5 µm in 1975, to 3 µm in 1978, and 1.5 µm in 1990 dramatically 
improved HPLC performance. The evolution of capillary columns culminated in the creation of 
fused silica columns and was directly connected to the developments in the fiber optics industry. 
In 1979 at the Third Hindelang Symposium R.D. Dandeneau and E.H. Zerenner reported (29) on 
production and use of flexible fused-silica columns. Their column tubing was adapted from the 
fiber optics tubing already manufactured at Hewlett-Packard, California. To prevent the cracks 
and breaks of the fragile fused silica, they coated the outside of the tubing immediately after 
drawing with silicone rubber (nowadays the fused silica tubing is coated with polyimide). 
Microscale LC-MS/MS was first used to analyze peptides by Donald Hunt (30). A typical 
contemporary nanoLC capillary column has a length of 10-15 cm; inner diameter 75-100 µm and 
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is packed with 3 or 5 µm C18 reversed phase particles. Most of the commercially available 
capillary columns are provided in the fritted format leaving it up to the end-user to choose spray 
capillaries with opening of 5-8 µm which is attached to the column through the tee union (Figure 
10). Such a set-up though acceptable to many has substantial drawbacks - in addition to 
introducing additional “void volume” leading to peak broadening and post-column mixing, the 
spray capillary opening is easily clogged by stray pieces of packing material.  Some groups 
suggested to pack media particles into the tapered capillary columns with the particles diameter 
being larger than the column opening (31). In this case, the tapered end acts both as emitter and 
restrictor for the packed material. The reported setup results in significant increase in 
backpressure of a chromatography system (typically more than 250 bars), common fluidic 
blockage and deleterious consequences on the pump performance.  In 2002 Yasushi Ishihama 
and Matthias Mann described a so-called “arch” concept of the capillary column packing (32). 
They suggested packing particles of a lesser diameter than a tapered end of the capillary column 
which also serves as an emitter. The particles produce self-assembled frits based on the stone 
bridge arch principle (Figure 11, 12). The created self-assembled frit is stable, results in a 
backpressure less than 180 bar for a typical capillary nanoflow setup, thus reducing the 
backpressures used in capillary LC (up to 300 bars) and eliminating post-column dilution of the 
analyte. The setup combining nano-LC system and spraying capillary column is nowadays the 
standard for introducing peptide samples into a mass spectrometer (Figure 13).  
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Figure 9. Capillary columns with inner diameter of 0.075 mm or less dramatically increase LC-
MS sensitivity. 
 
 
 
 
 
 
     
 
 
 
Figure 10. NanoLC connection for a fritted capillary column. 
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Figure 11.  Fused silica spraying capillary packed with 3µm C18 silica particles. X400 
magnification. 
                               
Figure 12. Columns utilizing arch types found in stone-bridges. (a) Tapered column with the 
„„keystone‟‟ arch, (b) tapered column with the „„double-stone‟‟ arch; (left picture) a stone-bridge 
with the keystone arch, (right picture) a stone-bridge with the double-stone arch. Taken from ref. 
(32). 
22
 
 
 
 
 
Figure 13.  Nano-LC set-up using spraying capillary column. 
 
 
The LC-MS/MS runs and protein database searches 
 
Modern  proteomics profiling methodology are based mostly on the so-called “shotgun”  
approach when MS data on the peptides resulting from the enzymatic digest of the protein 
mixture are collected at a high resolution and mass accuracy, and MS/MS fragmentation data are 
recorded at high speed with low resolution and accuracy maximizing sensitivity and throughput 
(33). The full MS scan provides information to choose a precursor ion mass for the following 
fragmentation event (Figure 14). The MS scan results in information about the mass and 
intensity of a precursor peptide (Figure 15a). The subsequent MS/MS fragmentation provides an 
amino acid sequence signature of the peptide (Figure 15b). Sequence database search algorithms 
are used to assign sequence information to MS/MS spectra (34-36). All peptide candidate 
sequences that match the experimental peptide mass within the allowed mass deviation are 
selected from an in silico digested protein sequence database. Each candidate is further processed 
at the MS/MS level by correlating the experimental and theoretical peptide fragmentation 
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patterns also within the allowed mass deviation. This produces a probabilistic score for the 
likelihood that the match is a false positive. Any of the „search engines‟ utilizes a scoring scheme 
calculating the significance of peptide assignments and provides theoretically or empirically 
derived statistical thresholds for assessment of peptide identifications. Figure 16a shows the 
results of a database search for a particular peptide.  All the peptide identifications per unique 
protein are aggregated and presented as a coverage map (Figure 16b). If the protein exists in the 
database that is searched and relevant MS and MS/MS spectra of reasonable quality are present, 
than the identification of such a protein by conventional computational methods is an easy task. 
Nevertheless, in a typical proteomics experiment the peptide identification rate rarely exceeds 
30%. One of the reasons for this are post-translational modifications (PTM) of proteins which 
result in a peptide mass shift (delta-mass, ∆M). The conventional search engines perform poorly 
in this case – before submitting the search a user has to have an a priori knowledge of the 
modifications (which is often not the case) and specify all potential modifications as “variable”. 
Allowing for many variable modifications in the database search increases the rate of false 
positives and requires a much higher score threshold for confident identification of peptides, 
which leads to an enhanced number of false negative results (37). This problem was approached 
with the recent introduction of the Modificomb software tool (38), which is based on the concept 
that most of the PTMs are present in substoichiometric amounts. Thus each peptide “family” will 
consist of an unmodified base peptide and several modified or „dependent‟ peptides with the 
same sequence but with a PTM. Modificomb searches for such families, “combs out” from large 
data arrays pairs of peptides with sequence identities one of which is a base peptide and the other 
of which is a dependent peptide (Figure 17). Often, the dependent peptide has similar 
chromatographic properties and thus appears in a narrow retention time (RT) window around the 
base peptide. ModifiComb separates the function of peptide identification from the function of 
the PTM assignment and is even able to use a lower information content from MS/MS data of 
modified peptides than is required for reliable database identification of unmodified peptides by 
conventional search engines. However, if the protein is absent in the database its identification is 
not possible using sequence database search algorithms – in such a case de-novo sequencing is 
needed. At this moment, several commercially available software tools for automated de-novo 
sequencing of the peptide spectra exist (39-41). In my opinion, even though these tools are 
extremely helpful in guiding users towards interesting hits, they are still not reliable and in many 
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cases it is the expert judgment of the experienced analyst which leads to the correct sequence and 
identification.  
 
 
 
 
 
 
 
 
Figure 14. LC-MS profile of a complex peptide mixture. During the MS scan ions are chosen for 
isolation and the following MS/MS fragmentation. 
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Figure 15. Information obtained during MS and MS/MS scans is used for peptide identification.  
(a) The peptide mass is calculated during the MS scan, (b) peptide internal composition is 
revealed during MS/MS scan. 
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Figure 16. Identification output of a protein identification software engine. Single peptide 
identifications (a) are added up to create a protein peptide coverage map (b). 
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Figure 17.  Modificomb algorithm (from ref. (38)). 
 
 
 
The quadrupole-time-of-flight mass spectrometer (Q-TOF) 
 
In my opinion, the Q-TOF mass spectrometer QSTAR introduced in the late 1990s by SCIEX 
was the first robust instrument generating high quality data obtainable in both MS and MS/MS 
modes which provided mass spectrometrists with the needed precision tools for investigating 
peptide structure and for de novo sequencing. Even though not as fast and accurate as the 
recently introduced orbitrap, the instrument was highly useful and popular in the proteomics 
community in the early 2000s.  An excellent Q-TOF tutorial was written by Igor Chernushevich 
of SCIEX, one of the instrument‟s inventors, in 2001 (9). The  Q-TOF tandem mass spectrometer 
of SCIEX can be described as a triple quadrupole with the detecting quadrupole section replaced 
by a TOF analyzer. An additional RF quadrupole Q0 is added to provide collisional damping, so 
the instrument consists of three quadrupoles, Q0, Q1 and Q2, followed by a reflecting TOF mass 
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analyzer with orthogonal injection of ions (Figure 18). The instrument combines filtering and 
MS/MS capabilities of the quadrupole analyzer with the accurate 20-50 parts per million (ppm) 
mass accuracy for detection in the TOF analyzer. For MS scans the quadrupoles operate in the 
radio frequency (RF) only mode, guiding ions to the TOF analyzer for detection. For MS/MS, 
Q1 is operated in the mass filter mode to transmit only the precursor ions of interest. The ions are 
then typically accelerated to between 25 and 50 eV before entering the collision cell Q2, where 
they undergo CID after collisions with neutral gas molecules. The resulting fragment ions are 
detected in the TOF part. In TOFMS, ions are resolved according to the formula: 
 
                                                  
 
where m and t are mass and flight time of the ion, Δm and Δt are the peak widths at the 50% level 
of the mass and time, respectively, Δz is the width of an ion packet in the vicinity of the detector 
and Leff is the effective length of the TOF analyzer. When R is determined from t, there is an 
adverse factor of 2 reducing the resolution, which originates from the square root dependence of 
the flight time on mass: 
 
                                                               
 
where Uacc is the full accelerating voltage in the TOF. 
A typical Q-TOF sequencing cycle would include 1 MS scan (1 sec) and 3 MS/MS (2-3 sec 
each) which amounts to 7-11 sec acquisition time. Even though this is significantly slower than 
the cycle time of ion trap mass spectrometers, the Q-TOF provides high quality data in both MS 
and MS/MS modes which improves the quality of protein identification, and undoubtedly 
stimulated future spectacular developments in high accuracy biological mass spectrometry.  
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Figure  18.   SCIEX QSTAR Q-TOF mass spectrometer (from ref. (9)). 
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The Orbitrap 
 
The orbitrap analyzer is an example of how an old concept, if resurrected at the right time by an 
exceptional inventor, can lead to the creation of a truly revolutionary device. As mentioned 
before, orbital trapping was originally introduced by Kingdon in 1923 (10). The Kingdon trap 
contains a wire extended along the axis of a cylinder. When a voltage is applied between the wire 
and the cylinder, the created field attracts externally introduced ions to the wire. Only the ions 
that have enough tangential velocity do not collide with the wire and survive - electrostatic 
attraction is compensated by centrifugal force arising from the initial tangential velocity. The 
ions start orbiting around the wire in a manner similar to planets orbiting around their sun. The 
shape of the outer cylinder creates a field curvature which restrains axial motion of the ions. The 
so-called “ideal” orbital trap was introduced about 50 years ago (42-44) – its outer cylinder 
electrode is elaborately shaped and ions are trapped in the field with the potential distribution: 
 
                                        
2 2 2( , ) / 2 ln( / )
2
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U r z z r R r R  
 
where r and z are cylindrical coordinates , k is the field curvature, and Rm is the characteristic 
radius (Figure  19). 
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Figure 19.  An ideal Kingdon trap (from ref. (45)). Ions are moving in spirals around the central 
electrode. 
 
 
 
Before the patent by Makarov (46) it was proposed to use the “ideal” Kingdon trap as a mass 
spectrometer with image current detection (47). However, the measurement of m/z ratios was 
based on the frequencies of ion rotations. This approach led to poor mass resolution because ion 
velocity and initial radius significantly influence the rotational frequency. Makarov‟s idea was to 
derive the m/z values from the frequency of harmonic ion oscillations along the field‟s axis - this 
frequency is completely independent of energy and spatial spread of ions. The axial frequency is 
detected by processing the image current with Fourier Transform (FT) algorithms. 
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Figure 20. Axial  oscillations of ions in the orbitrap do not depend on initial energy, angle and 
position of ions . ω is the oscillation frequency and k is an instrumental constant.  Adapted from 
ref. (45).  
 
 
The orbitrap measures mass with a very high accuracy of about 2-3 ppm. In addition to that, 
introduction of the so-called “lock-mass” option  utilizing  common ambient air contaminants 
(siloxane derivatives), which become ionized during electrospray,  as internal calibration 
standards routinely increases mass measurement accuracy to below 1 ppm (48). In order to 
achieve its maximum performance, the orbitrap has to operate at the very low pressure of 10
-10 
mbar. For this reason it is not practical to fragment the ions inside the orbitrap by the frequently 
used CID process which relies on much higher pressures of 10
-3
-10
-5 
mbar. The LTQ-Orbitrap 
hybrid instrument links the linear quadrupole ion trap (LTQ) (49) in tandem with the orbitrap. 
The linear ion trap is very sensitive and fast mass spectrometer used for guidance, storage, 
fragmentation and detection of ions even though it has relatively low resolution and accuracy. 
For peptide identification, mass accuracy of just 1 ppm for the precursor ion constrains peptide 
candidates to just a few sequences in the database, resulting in reduction of the false positive 
identifications, and, hence, greatly facilitates peptide identification (50). In the typical 
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proteomics set-up the precursor peptide masses are measured in the orbitrap (MS scan) with very 
high accuracy and the following fragmentation profiles are acquired in the LTQ with low 
resolution (MS/MS scans). The process is fast and, potentially, allows parallel operation which 
could lead to a rate close to 1 sec per cycle (1 cycle contains 1 MS scan and 5 MS/MS scans) 
(51). The obtained information is typically sufficient to identify a peptide product of a known 
protein in the database. Nevertheless, the quality of the MS/MS data obtained in the ion trap is 
not normally satisfactory if the need for manual de-novo interpretation of data arises. In this case, 
we can also perform fragmentation of the ions in the ion trap and forward the products into the 
orbitrap for high accuracy mass detection. Certainly the resulting data could be used for de novo 
analysis, however the design of the ion traps imposes a low mass cut-off restriction on the 
detectable product masses which usually corresponds to 1/3 of the precursor ion mass. Thus, 
such important MS/MS pieces of evidence as immonium, a2 and b2 ions (23) are not present, 
which could impede elucidation of peptide structure.  
  
 
 
 
 
 
 
Figure 21. LTQ-Orbitrap XL mass spectrometer (modified from ref. (52, 53). 
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Higher-energy C-trap dissociation (HCD) 
 
 
Recently, Olsen et al. showed that ions can be efficiently fragmented by high-accuracy and full-
mass-range tandem mass spectrometry (MS/MS) with a method termed higher-energy C-trap 
dissociation (HCD) (53). The C-trap, normally used to store ions on their way from the ion trap 
to the orbitrap, can also be used as a collision chamber to enable low energy CID fragmentation 
which yields y and b ion series typical for quadrupole-type CID. In this case, the fragmentation 
spectra are obtained over the full mass range and provide an analyst with useful information 
about the low m/z reporter ions. In the LTQ Orbitrap XL, the newest version of the LTQ-
Orbitrap line, fragmentation is performed in a separate octapole collision cell at the far end of the 
C-trap. The octapole collision cell is aligned with the C-trap. The cell contains nitrogen at low 
pressure as a collision gas. The collision cell is supplied with an RF voltage of which the direct 
current offset can be varied thus giving the opportunity of changing the values of collision 
energy (CE).  
The following example illustrates how adjusting the applied CE can be helpful for elucidation of 
post-translational modifications. O-linked sugars are very labile and can easily be destroyed 
during the mass spectrometric fragmentation event. Figure 22 presents a fragmentation spectrum 
of a naturally occurring glycosylated peptide product of pro-IGF2 from our cerebrospinal fluid 
(CSF) profiling study (54). This peptide, with sequence DVSTPPTVLPDNFPRYPVGKF, is 
modified by O-linked glycosylation at T-99 and carries the HexNAcHex(NeuAc)2 sugar. When 
the HCD fragmentation spectrum of the pro-IGF2- derived peptide was acquired with the CE 
value of 50, we observe a singly charged ion at m/z 274.092 corresponding to the dehydrated 
oxonium ion of sialic acid. We can also clearly follow the y-ion series, and bearing in mind the 
presence of a potential sugar attachment, we identified the peptide. Nevertheless, the information 
about the exact location of the modification, as well as its structure, is lost at this CE value. We 
found that by lowering the CE from 50 to 35 we did observe fragment ions pertaining to sugar 
attachments (Figure 23). In this case, the sugars are partially preserved which enables us not only 
to identify the O-linkage site but also to ascertain the glycosylation structure. As the direct result 
of this identification, we modified the MASCOT search engine to take the characteristic mass 
offsets of the discovered glycosylation signature into account. In this way we discovered some 
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novel neuropeptides solely as their glycosylated forms which, otherwise, would never have been 
found (54). 
 
 
 
Figure 22. DVSTPPTVLPDNFPRYPVGKF glycopeptide, HCD fragmentation at CE of 50. 
 
     
 
Figure 23. DVSTPPTVLPDNFPRYPVGKF glycopeptide, HCD fragmentation at CE of 35. 
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De-novo sequencing as a useful proteomics tool 
 
 
I consider peptide de-novo sequencing to be an extremely useful proteomics tool. I was trained 
as a biological mass spectrometrist about 10 years ago when search engines for mass 
spectrometric peptide data were yet to be made reliable and the accuracy of MS instrumentation 
was yet to improve. At that time, most of the peptide identifications demanded verification by 
experts, and, as a consequence, the time provided an excellent opportunity to learn the intricacies 
of MS/MS and the quintessence of de-novo peptide identification. Nowadays, sophisticated 
search engines provide answers to many submitted enquiries. Nevertheless, de-novo sequencing 
is still an indispensible tool for structure elucidation of unknown proteins and peptides, as well as 
characterization of post-translational modifications. In the presented publications, I used de-novo 
sequencing on a high accuracy and resolution mass spectrometer for identification and 
characterization of novel CSF neuropeptides, their post-translational modifications (54) as well 
as discovery of novel extended forms of nuclear proteins (55). 
 
Proteomics in genomics  
 
 
The Human Genome Project was completed in 2003 and provided scientists with the means for 
prediction of the protein-coding genes. Until recently, a lot of effort has been spent on the 
development of the bioinformatics-based tools for gene prediction and annotation. For 
mammalian genome annotation the Ensembl (56) and  NCBI (57) are the major processing 
gateways. Both cDNA-derived, evolutionary-derived and de novo approaches are used for the 
prediction of the protein-coding gene sequences. Even though eight years of bioinformatics 
progress have gone by since the Bork‟s publication in which he described the pitfalls of the gene 
prediction algorithms estimating the false positive rate of gene prediction to be at least 30% (58), 
his statement is still relevant nowadays. Obviously, no gene prediction pipeline is 100% fault-
safe. For the human genome, for example, de novo gene prediction approaches are estimated to 
be only 50% correct (59). High frequency of alternative splicing in mammalian genomes is one 
of the major contributors to erroneous gene assignments. For the verification of the predicted 
genes, the expression-based techniques are used most commonly.  The techniques involve RT-
PCR and direct sequencing of predicted protein-coding genes. While these methods can validate 
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the expression of the predicted gene, they do not provide an answer as to whether the expressed 
gene is translated into a protein. Proteomics identifies protein products of the genes and reports 
on the “real” output of the translation machinery. Hence, in addition to confirming predicted 
genes, proteomics can also supply information leading to discovery of novel genes, splice and 
edited gene variants. Genomics and proteomics are truly complementary of each other and, no 
doubt, in the future we will see the fusion of the two fields. A number of the recent initial studies 
reported on using proteomics tools to probe the genome (60-62). One of the most obvious ways 
to fish out novel genes from LC-MS/MS data is to perform a search against an EST or gene 
database. However, the queried database must be translated in six frames which, giving the 
complexity of the human genome, results in a huge database size (for comparison – a “normal” 
human protein sequence database has the size of about 40 MB, the translated EST human 
database  - 7 GB). Additionally, the size of the processed LC-MS/MS files obtained by 
contemporary high-throughput instrumentation is also massive and could easily go over a few 
gigabytes per proteome. This creates significant computational challenges for LC-MS/MS-based 
identification of novel protein-coding genes from genomic databases. The key need is currently 
for innovative computational approaches which will help to overcome the above-mentioned 
obstacles.  
 
Neuropeptidomics 
 
The neuropeptides are naturally occurring 3-100 amino-acid residues long polypeptides. It is 
now a common knowledge that neuropeptides, similarly to such classical neurotransmitters as 
amino acids, metabolites and biogenic monoamines, can target specific receptors and induce a 
wide spectrum of physiological responses. The first neuropeptide, substance P, was discovered 
by von Euler and Gaddum in 1931 (63). However, the amino acid composition of substance P 
was revealed only fifty years later when Chang and Leeman described cloning and sequencing of 
substance P (64). They showed that substance P is 11 amino-acid long peptide and C-terminally 
amidated. Neuropeptides are smaller than average proteins and present both in CNS and 
peripheral organs, their interaction with the target receptors is much stronger than that of small 
neurotransmitters (65). During a typical neuropeptide processing event, the signal peptide is 
removed from a protein precursor by a signal peptidase (66). The pro-peptide is cleaved by 
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specific convertases at dibasic sites generating precursors which then are acted upon by 
carboxypeptidases (67) giving rise to mature forms of neuropeptides. In addition to this, the 
peptides could be C-terminally amidated by peptidylglycine monooxigenase which requires a C-
terminal glycine in the peptide sequence (68). MS-based neuropeptidomics is a nascent and 
promising area of neuropeptide research (69).  Even though recent developments in capillary 
separation science and improvements in sensitivity and accuracy of mass spectrometers have 
provided scientists with necessary tools for discovery of novel neuropeptides, the identification 
of neuropeptides by LC-MS/MS is still challenging. In conventional proteome mapping 
experiments, proteins are digested with trypsin, and each protein is usually identified by at least 
two fully tryptic and unmodified peptides. Tryptic peptides which carry C-terminal basic amino 
acids are protonated under acidic conditions – the event facilitates their mass spectrometric 
fragmentation and consequent interpretation of the data. The identification of neuropeptides is 
much more challenging. They do not terminate in predictable amino acids, making the number of 
candidates to be considered in the database search much higher, and the nonstandard charge 
distribution within the peptide sequence can produce fragmentation spectra with a smaller 
number of characteristic ions. Importantly, neuropeptides can be post-translationally modified 
which additionally complicates their analysis. In many instances, researchers still have to rely on 
manual interpretation of the neuropeptide MS/MS fragmentation patterns. It is obvious that there 
is a huge demand for improved efficient computational platforms for the LC-MS/MS 
neuropeptide identification. 
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Presented work 
 
Proteomics as a tool for discovery of novel genetic editing mechanisms 
 
There is a widespread belief that thorough analysis of unassigned shotgun proteomics data could 
lead to discovery of novel genes, novel post-translational modifications or novel gene expression 
events (70). The data quality obtainable with modern high accuracy mass spectrometry greatly 
facilitates the attempts to „fish out‟ something novel from the depths of the proteomic.  However, 
until now three were almost no examples of useful biological data emerging from such attempts. 
Here, we used such information to discover a previously unknown mechanism creating altered 
protein forms (71).  
Linker histones H1 and high-mobility group (HMG) proteins are abundant nuclear proteins that 
regulate gene expression through modulation of chromatin structure. For a number of years, we 
have analyzed these proteins and have reported on their modifications in cell culture and in 
tissues (72, 73). A while ago we noticed that many fragmentation spectra of excellent quality 
could nevertheless not be mapped to any protein in the database. We then performed „de novo‟ 
sequencing on these peptides (Figure 24) and found, to our surprise, that they mapped just 
upstream of their respective genes.  
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Figure 24.   High accuracy MS/MS spectrum of the SSDSSLASPGAALQTGPVVR  peptide 
pertaining to the 5‟-UTR of h1.0. De-novo sequencing of the peptide provided a stimulus for 
further research and lead to discovery of the previously not reported insertion editing mechanism 
in humans. 
 
 
This was not due to an alternative, upstream start codon because the 5‟UTRs do not contain any 
such stop codon. We then analyzed expressed sequence tag (EST) databases and found that some 
EST sequences contained an additional, inserted uridine, creating a novel AUG start site.  
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 Predicted ET part of H1.0  
 
 
ggatgctgggaaaagggaggcagaggaggcggaggcagaggcagaggcagagcccggtgccg 
   M  L  G  K  G  R  Q  R  R  R  R  Q  R  Q  R  Q  S  P  V  P  
agaccaagcgacagaccggcggggctgggcctcgcaaagccggctcggcgagctctcccg 
 R  P  S  D  R  P  A  G  L  G  L  A  K  P  A  R  R  A  L  P  
acacccgagccggggaggaaaagcagcgactcctcgctcgcatccccgggagccgcactc 
 T  P  E  P  G  R  K  S  S  D  S  S  L  A  S  P  G  A  A  L  
cagactggcccggtagtcaggggctcaggagcagatcccgaggcaggctttgctcagcct 
 Q  T  G  P  V  V  R  G  S  G  A  D  P  E  A  G  F  A  Q  P  
ccgacgagggctggccctttggaaggcgccttcaacagccggaccagacaggccaccatg… 
 P  T  R  A  G  P  L  E  G  A  F  N  S  R  T  R  Q  A  T  M…  
 
Figure 25. Sequence coverage of the extended (ET) part of H1.0.  
 
While RNA insertion has not been described in metazoans, it is not completely unprecedented in 
biology and may resemble the RNA editing mechanism described for trypanosomatid protozoans 
in which the uridine insertion/deletion-based RNA editing of the mitochondrial mRNA creates 
new initiation/termination codons (74). During the last years we have raised antibodies against 
these proteins and characterized their localization and behavior. Interestingly, we find that they 
are regulated differently from their „parent genes‟ - the extended (ET) form of histone H1, for 
example, found in splicing speckles, is upregulated upon apoptotic treatment with vinblastine 
and TNF-alpha, whereas H1 itself is not affected by the treatment. The N-terminally extended 
proteins occur in normal human cells and their synthesis is not related to alterations at the DNA 
level. For the described examples, the amounts of ET-proteins appear to be about two orders of 
magnitude lower than those of the standard products of the corresponding genes. However, since 
H1.0 and HMGN1 occur in about 10
6
-10
7
 copies per cell the ET forms are still relatively 
abundant compared to transcription factors and other chromatin proteins with specific regulatory 
functions. Presumably, the ET-proteins were not identified until now because they are not 
predictable from the corresponding genes and they occur „in the shadow‟ of their normal forms. 
Thus, in the past, the ET-proteins were probably observed in many experiments but simply 
ignored as artifacts - as evident from Figure 26 commercial antibody against HMGN1 recognizes 
both “normal” and the extended versions of this protein. 
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Figure 26. Western blots of perchloric acid extracts of MCF7 cells probed with antibodies 
against ET-HMGN1 and HMGN1, respectively. 
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Summary
Large-scale analysis directly at the protein level holds the
promise of uncovering features not apparent or present at
the gene level [1–3]. Although mass spectrometry (MS)-
based proteomics can now identify and quantify thousands
of cellular proteins in large-scale proteomics experiments,
much of the peptide information contained in these experi-
ments remains unassigned [4]. Here, we use such informa-
tion to discover a previously unreported mechanism
creating altered protein forms. Linker histones H1 and
high-mobility group (HMG) proteins are abundant nuclear
proteins that regulate gene expression through modulation
of chromatin structure [5–8]. In the high-resolution MS anal-
ysis of histone H1 and HMG protein fractions isolated from
human cells, we discovered peptides that mapped upstream
of the known translation start sites of these genes. No alter-
native upstream start site exists in the genome, but analysis
of Expressed Sequence Tag (EST) databases revealed that
these N-terminally extended (ET) proteins are due to in-
frame translation of the 50 untranslated region (50UTR) se-
quences of the transcripts. The new translation start sites
are created by a single uridine insertion between AG, reflect-
ing a previously unreported RNA-editing mechanism. To our
knowledge, this is the first report of RNA-insertion editing in
humans and may be an example of the type of discoveries
possible with modern proteomics methods.
Results and Discussion
Identification of N-Terminally Extended (ET) Proteins
In-depth proteomic analysis of nuclear extracts from various
human cell lines revealed a multitude of posttranslational mod-
ifications in linker histone H1 and high-mobility group (HMG)
proteins [9]. Apart from this, we found a number of fragmenta-
tion spectra of excellent quality that could not be matched to
any protein sequence or open reading frame (ORF) in the
*Correspondence: mmann@biochem.mpg.de (M.M.), jwisniew@biochem.
mpg.de (J.R.W.)4human International Protein Index (IPI) database. We therefore
extracted partial de novo sequences from these fragmentation
spectra. When searching the NCBI dbEST database [10] with
these sequences, we found that they matched directly up-
stream of the start codon and within the 50UTR of h1.0. Simi-
larly, we also found peptides pertaining to the 50UTR of the
hmgn1 gene. This was surprising because in both cases, the
50UTRs do not contain any alternative start codons.
To characterize the N-terminally extended (ET) sequences of
H1.0 and HMGN1, we partially purified these proteins from
MCF7 cells by reversed-phase chromatography, resolved frac-
tions by SDS PAGE (Figure 1A), digested them with trypsin, and
analyzed peptide mixtures by online liquid-chromatography
mass spectrometry (LCMS). We identified a total of eight
unique peptides (including one phosphopeptide) of ET-H1.0
and two unique peptides of ET-HMGN1 using high-resolution,
high-mass-accuracy MS. Several of these peptides were
further verified by high-resolution fragmentation analysis with
low ppm accuracy (see Appendices S1 and S2, available on-
line). Fragmentation spectra of the identified peptides contain-
ing the ‘‘normal’’ initiation methionine, as well as the peptides
most proximal to the N termini of ET-H1.0 and ET-HMGN1,
are shown in Figure 1. We identified two forms of ET-H1.0, vis-
ible as two bands in SDS PAGE, and a single form of ET-HMGN1
(Figure 1F). On the basis of the mapped peptides, the long and
short ET extensions of H1.0 comprise at least 86 and 63 amino
acid residues, respectively, whereas the ET extension of
HMGN1 is at least 23 amino acid residues in length. Due to their
amino acid composition, the high number of the basic residues,
and the low number of the hydrophobic residues, histones have
reduced mobility in SDS PAGE. With respect to the molecular
weight (MW) markers, H1 histones appear at a MW of 30,000–
35,000 Da. However, their molecular masses are in the range
of 20,000–22,000 Da. This is the reason that the ET-H1.0 forms
appear to have MWs close to 40,000 Da.
New Translation Start Sites Are Created
by a Single Uridine Insertion
We then searched the NCBI dbEST database for EST frag-
ments containing the 50UTR of h1.0 and found 11 sequences,
derived from different tissue sources, with a uridine (U) inser-
tion (the NCBI dbEST database release of August 06, 2008
contains 301 ESTs carrying the h1.0 50UTR, 11 of them with
U insertion). In each case, this insertion happened at the
same position—297 bp upstream of the known start codon—
between the A and G bases at the AGCT location (Figure 2B,
Appendices S3, S4, and S5). For hmgn1, we likewise found
an EST sequence in which a new start codon is potentially cre-
ated by U insertion, in this case 135 nt upstream of the known
start codon (Appendices S3 and S5). With these start sites, the
identified peptides cover 85% and 50% of the predicted se-
quences of ET-H1.0 and ET-HMGN1, respectively (Figure 2A).
h1.0 occurs as a single gene in the genome database. To
exclude the existence of a genomic form of ET-h1.0, we per-
formed PCR analysis of genomic DNA for the sequence sug-
gested by the EST data. The ‘‘normal’’ h1.0 gene has an AluI
restriction site (50-AG/CT-30) in its 50UTR sequence at the posi-
tion where the U insertion was found in some EST sequences4
N-Terminally Extended Human Proteins
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1762Figure 2. Primary Structure and Putative Origin of ET
Proteins
(A) Schematic view of the proteins with extension of
their termini (ET) originating from translation of the
50UTRs. Black, canonical translation products;
green, sequenced by high-resolution mass spec-
trometry; blue, predicted primary structure of the
ET-H1.0 and ET-HMGN1 proteins.
(B) AGCT site with the T insertion (arrow) in EST se-
quences coding for ET proteins.
(C) The AluI site of the ‘‘normal’’ h1.0 sequence is im-
paired by the creation of the new start codon.
(D) The 200 bp sequence containing the base inser-
tion site (red bold) was amplified with genomic DNA
isolated from MCF7 cells. The sequences of the
used primers are underlined.
(E) The 200 bp PCR product was obtained only from
AluI-undigested templates. Lane1, the DNA template
was digested with AluI prior to the PCR reaction;
Lane 2, the PCR reaction with intact template; Lanes
3 and 4, the 200-bp product from lane 2 was ex-
tracted from the gel and incubated in the presence
or absence of AluI, respectively.(Figure 2C). The insertion creates a new start codon and
impairs the AluI-restriction site. Thus, amplification of the
200 bp sequence (Figure 2D) from AluI-treated DNA would
allow identification of the modified fragment, and the PCR
product obtained from the undigested template would be sus-
ceptible toAluI digestion. The PCR reactions revealed that nei-
ther was the 200 bp fragment amplified from the AluI-digested
template nor was the 200 bp PCR product from the undigested
template cleavable by the endonuclease (Figure 2E). These re-
sults disprove the presence of h1.0 gene sequence coding for
N-terminally extended H1.0, confirming that the new start
codon is created during or after transcription of h1.0 by an
RNA editing process. It is possible that the hmgn1 mRNA is
processed by the same mechanism as that of h1.0. While
RNA insertion has not been described in metazoans, it is not
completely unprecedented in biology and may resemble the
RNA editing mechanism described for trypanosomatid proto-
zoans in which the uridine insertion/deletion-based RNA edit-
ing of the mitochondrial mRNA creates new initiation/termina-
tion codons [11]. The resulting N-terminal protein sequences
can carry unique properties such as, for example, DNA binding
[12]. The human 50UTRs of H1.0 and HMGN1 have no obvious
similarities with uridine insertion regions in the trypanosomatid
mitochondrial genes. These regions also are not conserved
between species.
ET Proteins Occur Abundantly in Human Cells
To characterize ET-H1.0 and ET-HMGN1 in human cells and tis-
sues, we raised antibodies in rabbits against peptides derived46from the N-terminal extensions and used the affinity-purified
antibodies for western blot and immunofluorescence staining
analyses (Figure 3). The western blot analyses revealed that
both forms of ET-H1.0 were present in human breast- and
lung-cancer cells but not in HeLa cells (Figure 3A). ET-H1.0
was also detected in extracts from three human-cancer tissues
and three normal tissues (Figure 3A). Although ET-H1.0 was al-
ways accompanied by H1.0, its abundance did not correlate
with the observed amounts of H1.0. For example, normal
breast tissue and cancerous breast tissue from the same
patient contained similar amounts of H1.0, whereas the abun-
dance of the ET-H1.0 fluctuated (Figure 3A, lanes 4–9).
Immunofluorescence staining of MCF7 cells revealed
a bright-speckled staining pattern of interphase nuclei (Figures
3B and 3C), and its staining pattern was distinct from that of
H1.0 (Figures 3G and 3H). During mitosis, ET-H1.0 appears to
be in the vicinity of condensed chromosomes (arrows in Figures
3B and 3C). Control staining of HeLa cells, in which we were not
able to detect ET-H1.0 (see above), resulted in the absence of
staining (Figures 3D and 3E). The preferential nuclear location
of ET-H1.0 was confirmed by fractionation of MCF7 cells into
nuclear and low-speed cytosolic fractions followed by western
blotting (Figure 3G). Staining via a monoclonal H1.0 antibody
was distinct from that via its ET form (Figures 3G and 3H).
We found that ET-H1.0 colocalizes with splicing speckles
(Figures 3I–3L). The splicing speckles, subnuclear structures
identified by immunofluorescence microscopy, are thought
to mirror the interchromatin granule clusters detected by elec-
tron microscopy. The most widespread belief is that theFigure 1. Identification of Linker Histone and HMG Proteins with Extra Terminal (ET) Extensions Created upon Translation of the 50-Untranslated Regions
(A) Localization of ET-H1.0 and ET-HMGN1 in PAGE-separated nuclear protein fractions of MCF7 cells.
(B and C) Fragmentation spectra of tryptic peptides carrying the regions from both the ET extension and the ‘‘normal’’ protein parts of ET-H1.0 and
ET-HMGN1, respectively.
(D and E) Fragmentation spectra of tryptic peptides carrying the most N-terminally identified sequences of the ET extension of ET-H1.0 and ET-HMGN1,
respectively. See [25] for explanation of peptide fragmentation.
(F) Putative primary structure of the ET proteins. Bold text indicates experimentally observed ET extension; underlined text indicates sequences of inden-
tified peptides. pS denotes phosphoserine. Negative numbering is used for amino acid residues in the ET extensions. Arrows indicate the primary structures
of the long (l) and short (s) ET-H1.0 forms.
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1763speckles serve as depots of mRNA splicing factors and supply
the needed factors at the demand of the translation machinery
[13]. Even so, with some reports showing that the splicing
speckles could themselves operate as transcription sites
[14], their function remains obscure. A number of nuclear pro-
teins are guided to the speckles through the arginine-and-
serine-rich domain [15]. It is possible that a built-in message
in the ET sequence also directs ET-H1.0 toward the splicing
speckles.
We also performed western blot analyses with the anti-ET-
HMGN1 antibodies. This revealed that ET-HMGN1 is present
in the nuclear fraction of MCF 7 cells and, like ET-H1.0, occurs
in all analyzed normal and cancerous tissues (Figure 3M). We
estimated the relative abundance of ET-HMGN1compared to
HMGN1 to be about 1:50 (Appendix S6).
Abundance of ET-H1.0 Generally Does Not Correlate
with H1.0
Having established the existence and cellular localization of
the ET proteins, we then searched for their possible
Figure 3. Occurrence of ET-H1.0 and ET-HMGN1 in
Human Cells and Tissues
(A) Occurrence of ET-H1.0. Lanes 1–3, western blot
analysis of perchloric acid extracts of cervical-,
breast-, and lung-cancer cells, respectively. Lanes
4–9, extracts of three pairs of tissue, each matching
the same patient (1, 2, or 3), of normal breast
(No) and ductal invasive carcinoma G2 (Ca). Lanes
10 and 11, ovarian tumor. Lanes 11 and 13, normal
colon and colon adenocarcinoma G2. The blots
were probed with anti-ET-H1.0 and H1.0 antibodies.
(B–E) Nuclear localization of ET-H1.0 in MCF7 cells
(B–D); absence of fluorescence in HeLa cells, which
express little or no ET-H1.0 (E); fluorescent staining
of nuclei with DAPI (B and D); and immunofluorescent
staining with anti-ET-H1.0 antibodies (C and E).
(F) Western blot analysis of purified nuclei (lane 2)
and cytosolic fraction (lane 3) of MCF7 cells. Lane
1, perchloric acid extract reference.
(G and H) Double immunofluorescent staining of the
MCF7 nucleus with ET-H1.0 (green) and H1.0 (red)
antibodies, respectively.
(I–L) Double immunofluorescent staining of the MCF7
nucleus with anti-ET-H1.0 (J) and SC-35 (K) anti-
bodies, respectively; DNA staining with DAPI (I);
and merged (J) and (K) (shown in [L]).
(M) Expression of ET-HMGN1. Lanes 1–3 as in (F).
Lanes 4–7, extracts of two pairs, each matching the
same patient (1 or 2), of normal breast (No) and ductal
invasive carcinoma G2 (Ca) tissue samples. Lane 8,
ovarian tumor. Lanes 9 and 10, normal colon and co-
lon adenocarcinoma G2.
regulation in biological processes. Buty-
rate is known to reduce the growth of
many cell types, causing an arrest in the
G1 phase of the cell cycle [16]. In HeLa
S3 cells, the synthesis of H1.0 occurs at
a very low level (mRNA and protein) but
is dramatically augmented by butyrate
treatment [17]. We found that in the buty-
rate-stimulated cells, high expression
levels of H1.0 were accompanied by sub-
stantial increase of ET-H1.0. The increase
was detectable on western blots (Figures
4A and 4B) and by immunofluorescence staining (Figures
4E and 4F).
Given that butyrate has been shown to induce apoptosis in
human cancer cells [18], we decided to analyze the occurrence
of H1.0 and its ET-H1.0 forms upon apoptosis induced by DTT
[19], Vinblastine [20], and TNF-a [21]. Unlike the case of buty-
rate stimulation, in the cells treated with DTT, Vinblastine,
and TNF-a, only ET-H1.0 was augmented. The strongest in-
duction of ET-H1.0 was observed after treatment of the cells
with DTT or TNF-a for 30 hr. In apoptotic cells, ET-H1.0 was
localized in the shrunken and vacuolarized nuclei within the
condensed chromatin, but the ET-H1.0-containing speckles
were also observed outside the nuclei. These results suggest
that the levels of ET-H1.0 are regulated independently of trans-
lation of h1.0 gene. The nature of this regulation mechanism,
as well as a potential role of ET-H1.0 in differentiation and ap-
optosis, remains to be elucidated. Given that the N-terminal-
extension region of ET-H1.0 is highly basic (pI > 12), we spec-
ulate that it could increase the tightness of histone binding to
DNA. In this way, the extension could lead to formation of more47
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1764compacted chromatin that is characteristic of both terminally
differentiated and apoptotic cells.
Conclusions
Our work presents strong evidence that some 50-noncoding
sequences of human genes can be translated into proteins
upon creation of the new start codon during or after transcrip-
tion. The N-terminally extended proteins occur in normal hu-
man cells, and their synthesis is not related to alterations at
the DNA level. For the examples described here, the amounts
of ET proteins appear to be about two orders of magnitude
lower than those of the standard products of the correspond-
ing genes. However, given that H1.0 and HMGN1 occur in
about 106–107 copies per cell [22–24], the ET forms are still rel-
atively abundant compared to transcription factors and other
chromatin proteins with specific regulatory functions. Presum-
ably, the ET proteins were not identified until now because
they are not predictable from the corresponding genes and
occur ‘‘in the shadow’’ of their normal forms. Thus, in the
past, the ET proteins were probably observed in many exper-
iments but simply ignored as artifacts. The discovery of two ET
proteins implies the existence of a dedicated enzymatic ma-
chinery of RNA editing, which is probably used more widely.
Modern high-resolution MS data may already contain many
more examples of unexpected protein forms, which could be
brought to light by in-depth informatics analysis.
Experimental Procedures
The experimental procedures are described in the Supplemental Data file,
available online.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures and six
appendices and can be found with this article online at http://www.
current-biology.com/S0960-9822(08)01294-3.
Figure 4. In HeLa S3 Cells, ET-H1.0 Can Be Stimulated by Butyrate and
Other Agents, Causing Apoptosis
(A) Western blot analysis of perchloric acid extracts of HeLa S3 cells
treated with butyrate, DTT, Vinblastine, and TNFa. The blots were
probed with anti-ET-H1.0 and H1.0 antibodies.
(B) Western blot analysis of whole lysates of the untreated (lane 1), bu-
tyrate-treated, and DTT-treated cells (24 hr).
(C–H) Immunofluorescence analysis of cells treated with butyrate and
DTT. (C), (E), and (G): anti-ET-H1.0 staining. (D), (F), and (H): merged an-
tibody and DAPI staining.
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Supplemental Experimental Procedures 
  
 
Human tissue 
Human tissue was retrieved during surgery. Informed consent was obtained, and the 
study was approved by the local ethics committee (Medical Academy of Wroclaw, 
Poland).  
 
Cell culture  
All cells were grown under 5% CO2 at 37°C. MCF7, HeLa and A549 cells were grown in 
DMEM medium (GIBCO) supplemented with 10% fetal bovine serum (FBS). HeLa S3 cells 
were grown in suspension in RPMI 1640 medium (GIBCO) supplemented with 10% FBS. 
Exponentially growing HeLa S3 cells were subjected to treatment with 5 mM butyrate 
for 24 hours, 5 mM DTT for 5, 30 and 48 hours, 80 nM Vinblastine for 5, 30 and 48 
hours, and 150 ng/ml TNF‐α for 5, 30 and 48 hours.   
 
Protein extraction from human tissue and cultured cells 
The entire protein extraction procedure was carried out at 4°C in a cold room. 0.4‐2 g of 
frozen tissue was cut into small pieces and extracted with 3 vol. (m/v) of 5 % (v/v) HClO4 
using an IKA Ultra Turbax blender at maximum speed of approximately 25,000 rpm for 
20‐30 s and centrifuged at 15,000 × g for 5 min. Fat was removed from the top of the 
tubes with a spatula, the supernatant was collected and the pellet was re‐extracted with 
3 vol. of 5 % (v/v) HClO4. Proteins were precipitated from the combined supernatants 
with 33% (w/v) CCl3COOH for 30 min and collected by centrifugation at 15,000 × g for 10 
min. Culture cells were extracted with 5 % (v/v) HClO4 using three freezing/thawing 
cycles as described previously [1].  
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LC‐MS/MS analysis 
In‐gel protein tryptic digestion was performed essentially as previously described [2]. 
The resulting peptide mixtures were desalted using in‐house made C18 STAGE tips [3], 
vacuum‐dried and reconstituted in 0.5% acetic acid prior to analysis. 
Peptide mixtures were separated by online reversed‐phase nanoscale capillary liquid 
chromatography and analyzed by electrospray tandem mass spectrometry. The LC‐
MS/MS setup was similar to that described before [4]. Samples were injected onto an 
in‐house made 15 cm reversed phase spraying fused‐silica capillary column (inner 
diameter 75 μm, packed with 3 μm ReproSil‐Pur C18‐AQ media (Dr. Maisch GmbH, 
Ammerbuch‐Entringen, Germany), using either Agilent 1100 nanoflow (Agilent 
Technologies, Palo Alto, CA) or Proxeon EASY‐nLC (Proxeon Biosystems, Odense, 
Denmark) systems. The LC setup was connected to either LTQ Orbitrap or LTQ‐FT mass 
spectrometers (Thermo Electron, Bremen, Germany) equipped with a nanoelectrospray 
ion source (Proxeon Biosystems, Odense, Denmark). The peptides were separated with 
100 or 200 min gradients from 5 to 40% CH3CN in 0.5% acetic acid.  Data‐dependent 
acquisition was employed. Survey MS scans were acquired either in the orbitrap with 
the resolution set to a value of 60,000 or in FT cell with the resolution set to a value of 
100,000. Up to the five most intense ions per scan were fragmented and analyzed in the 
linear trap. Additionally, high accuracy analysis of fragmentation was also performed in 
the orbitrap with the resolution set to 15,000.The lock‐mass option was used as 
previously described for increased accuracy in mass measurements [5]. The spectra 
were searched either against an NCBI Human EST database or in‐house created 
database containing the sequences of ET‐ proteins with the use of MASCOT (Matrix 
Science, London, UK) search engine [6] followed by manual verification.  
 
Antibodies  
Antibodies against ET extension of H1.0 and HMGN1 were elicited in rabbits using 
RAGPLEGAFNSRTR peptide (residues ‐17 – ‐4) and LPRRHPARAFPAA (residues ‐14– ‐2), 
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respectively. The peptides were conjugated to ovalbumin (Imject Maleimide Activated 
Ova, Pierce). Animals were injected with 0.2 mg of crosslinked protein. Mono‐specific 
antibodies were purified on affinity columns which were prepared by coupling of 
individual peptides to iodoacetate activated gel (SulfoLink, Pierce) according to the 
manufacturer’s protocol. Antibodies against H1.0, HMGN, and SC‐35 were purchased 
from Biozol (mouse monoclonal ab 11079, Eching, Germany), ABCAM (rabbit polyclonal 
ab 5212, Cambridge, UK), and Novus Biologicals (mouse monoclonal, NB100‐1774, 
Littleton, USA), respectively. 
 
Western blot analysis 
For Western analysis, proteins were transferred from SDS gels onto the 
nitrocellulose membrane by electroblotting at 10 V/cm for 40 min. The proteins were 
crosslinked to the membrane by incubation in 0.5% (v/v) glutaraldehyde in PBS for 10 
min. The membranes were blocked with 10% (v/v)  normal goat serum (NGS) for 30 min 
prior to incubation with the primary antibodies together with 1% NGS in PBS containing 
0.1% Tween 20 (PBS‐T). Following 2 h incubation, the membrane was extensively 
washed with PBS‐T. Primary antibodies were visualized on the membrane with ECL 
peroxidase‐conjugated IgGs.  
 
Immunofluorescence  
Cells were fixed in methanol at ‐20°C for 3 min and nonspecific binding was 
blocked by incubation in 10% (v/v) normal goat serum. The affinity purified primary 
polyclonal antibodies against the ET‐extension of H1.0 were used at concentration of 2 
μg/ml. The monoclonal anti‐H1.0 was used at concentration of 25 μg/ml. The primary 
antibodies were visualized with secondary AlexaFluor488 or 546 goat antibodies 
(Molecular Probes) at concentration of 2.6 μg/ml. Nuclei were counterstained with DAPI 
at concentration of 1 μg/ml. Analyses were performed using LEICA TCS SP2 Confocal 
Laser Scanning Microscope. 
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Appendix S1. MS/MS Spectra of the Intrinsic ET-H1.0 Peptides 
 
Spectra for the depicted ET-H1.0 peptides were obtained by 
fragmenting the peptides in the linear ion trap section of a hybrid 
linear ion trap orbitap instrument (LTQ-Orbitrap). Fragments were 
transferred to the orbitrap and measured with high resolution (15,000) 
and with low parts per million mass accuracy. Together with the 
excellent representation of canonical b and y ions, this establishes 
the identity of the peptides with virtually complete certainty. 
 
 
 
Peptide       M/Z Charge
Mass 
observed, Da 
Mass 
calculated, Da 
Delta 
mass, Da 
AGPLEGAFNSR 559.783005 2 1117.551458 1117.551559 -0.000101
GSGADPEAGFAQPPTR 779.368752 2 1556.722952 1556.721878 0.001074
PSDRPAGLGLAK 394.559129 3 1180.655559 1180.656372 -0.000813
QATMoxTENSTSAPAAK 762.351853 2 1522.689154 1522.693329 -0.004175
QATMoxTENSTSAPAAKPK 583.620661 3 1747.840155 1747.841049 -0.000894
QRQSphosPVPR 524.258236 2 1046.50192 1046.502213 0.000293
RALPTPEPGR 547.308827 2 1092.603102 1092.603958 -0.000856
SSDSSLASPGAALQTGPVVR 950.493481 2 1898.97241 1898.969711 0.002699
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Appendix S2. MS/MS Spectra of the Intrinsic ET-HMGN1 Peptides 
 
 
 
 
Peptide           M/Z Charge Mass observed, Da Mass calculated, Da Delta mass, Da
AFPAATMoxPK 475.242370 2 948.470188 948.473877 -0.003689
RGPQAPGTR 470.258391 2 938.502230 938.504578 -0.002348
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Appendix S3. Human EST Sequences Pertaining to ET-H1.0 and ET-
HMGN1 
 
 
 
Human EST Sequences Pertaining to ET-H1.0 
 
GenBank    accession # Origin 
BX328722 Placenta 
BX371207 Jurkat cell line 
BX386531 Jurkat cell line 
BX397992 Placenta 
BX410654 Fetal brain 
BX418456 Fetal brain 
BX432449 Fetal brain 
BX432450 Fetal brain 
BX410653 Fetal brain 
BX426875 Fetal liver 
BX419072 Fetal brain 
 
 
A Human EST Sequence Pertaining to ET-HMGN1 
 
GenBank    accession # Origin 
CV807291 Blastocyst 
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Appendix S4. Multiple Sequence Alignment of ET-H1.0 ESTs 
Carrying the Insertion 
 
Only the ET part of the alignment is shown. 
 
BX397992        -GGATGCTGGGAAAAGGGAGGCAGAGGAGGCGGAGGCAGAGGCAGAGGCAGAGCCCGGTG 59 
BX432450        -GGATGCTGGGAAAAGGGAGGCAGAGGAGGCGGAGGCAGAGGCAGAGGCAGAGCCCGGTG 59 
BX418456        -GGATGCTGGGAAAAGGGAGGCAGAGGAGGCGGAGGCAGAGGCAGAGGCAGAGCCCGGTG 59 
BX371207        -GGATGCTGGGAAAAGGGAGGCAGAGGAGGCGGAGGCAGAGGCAGAGGCAGAGCCCGGTG 59 
BX419072        GGGATGCTGGGAAAMGGGAGGCAGAGGAGGCGGAGGCAGAGGCAGAGGCAGAGCCCGGTG 60 
BX386531        -GGATGCTGGGAAAAGGGAGGCAGAGGAGGCGGAGGCAGAGGCAGAGGCAGAGCCCGGTG 59 
BX432449        -GGATGCTGGGAAAAGGGAGGCAGAGGAGGCGGAGGCAGAGGCAGAGGCAGAGCCCGGTG 59 
BX426875        GGGATGCTGGGAAAARGGAGGCAGAGGAGGCGGAGGCAGAGGCAGAGGCAGAGCCCGGTG 60 
BX328722        -GGATGCTGGGAAAAGGGAGGCAGAGGAGGCGGAGGCAGAGGCAGAGGCAGAGCCCGGTG 59 
BX410653        -GGATGCTGGGAAAAGGGANGCAGAGGAGGCGGAGGCAGAGGCAGAGGCAGAGCCCGGTG 59 
BX410654        -GGATGCTGGGAAAAGGGAGGCAGAGGAGGCGGAGGCAGAGGCAGAGGCAGAGCCCGGTG 59 
                 *************  *** **************************************** 
 
BX397992        CCGAGACCAAGCGACAGACCGGCGGGGCTGGGCCTCGCAAAGCCGGCTCGGCGAGCTCTC 119 
BX432450        CCGAGACCAAGCGACAGACCGGCGGGGCTGGGCCTCGCAAAGCCGGCTCGGCGAGCTCTC 119 
BX418456        CCGAGACCAAGCGACAGACCGGCGGGGCTGGGCCTCGCAAAGCCGGCTCGGCGAGCTCTC 119 
BX371207        CCGAGACCAAGCGACAGACCGGCGGGGCTGGGCCTCGCAAAGCCGGCTCGGCGAGCTCTC 119 
BX419072        CCGAGACCAAGCGACAGACCGGCGGGGCTGGGCCTCGCAAAGCCGGCTCGGCGAGCTCTC 120 
BX386531        CCGAGACCAAGCGACAGACCGGCGGGGCTGGGCCTCGCAAAGCCGGCTCGGCGAGCTCTC 119 
BX432449        CCGAGACCAAGCGACAGACCGGCGGGGCTGGGCCTCGCAAAGCCGGCTCGGCGAGCTCTC 119 
BX426875        CCGAGACCAAGCGACAGACCGGCGGGGCTGGGCCTCGCAAAGCCGGCTCGGCGAGCTCTC 120 
BX328722        CCGAGACCAAGCGACAGACCGGCGGGGCTGGGCCTCGCAAAGCCGGCTCGGCGAGCTCTC 119 
BX410653        CCGAGACCAAGCGACAGACCGGCGGGGCTGGGCCTCGCAAAGCCGGCTCGGCGAGCTCTC 119 
BX410654        CCGAGACCAAGCGACAGACCGGCGGGGCTGGGCCTCGCAAAGCCGGCTCGGCGAGCTCTC 119 
                ************************************************************ 
 
BX397992        CCGACACCCGAGCCGGGGAGGAAAAGCAGCGACTCCTCGCTCGCATCCCCGGGAGCCGCA 179 
BX432450        CCGACACCCGAGCCGGGGAGGAAAAGCAGCGACTCCTCGCTCGCATCCCCGGGAGCCGCA 179 
BX418456        CCGACACCCGAGCCGGGGAGGAAAAGCAGCGACTCCTCGCTCGCCTCCCCGGGAGCCGCC 179 
BX371207        CCGACACCCGAGCCGGGGAGGAAAAGCAGCGACTCCTCGCTCGCATCCCCGGGAGCCGCA 179 
BX419072        CCGACACCCGAGCCGGGGAGGAAAAGCAGCGACTCCTCGCTCGCATCCCCGGGAGCCGCA 180 
BX386531        CCGACACCCGAGCCGGGGAGGAAAAGCAGCGACTCCTCGCTCGCATCCCCGGGAGCCGCA 179 
BX432449        CCGACACCCGAGCCGGGGAGGAAAAGCAGCGACTCCTCGCTCGCATCCCCGGGAGCCGCA 179 
BX426875        CCGACACCCGAGCCGGGGAGGAAAAGCAGCGACTCCTCGCTCGCATCCCCGGGAGCCGCA 180 
BX328722        CCGACACCCGAGCCGGGGAGGAAAAGCAGCGACTCCTCGCTCGCATCCCCGGGAGCCGCA 179 
BX410653        CCGACACCCGAGCCGGGGAGGAAAAGCAGCGACTCCTCGCTCGCATCCCCGGGAGCCGCA 179 
BX410654        CCGACACCCGAGCCGGGGAGGAAAAGCAGCGACTCCTCGCTCGCATCCCCGGGAGCCGCA 179 
                ******************************************** **************  
 
BX397992        CTCCAGACTGGCCCGGTAGTCAGGGGCTCAGGAGCAGAWCCCGAGGCAGGCTTTGCTCAG 239 
BX432450        CTCCAGACTGGCCCGGTAGTCAGGGGCTCAGGAGCAGATCCCGAGGCAGGCTTTGCTCAG 239 
BX418456        CTCCAGACTGGCCCGGTAGTCAGGGGCTCAGGAGCAGATCCCGAGGCAGGCTTTGCTCAG 239 
BX371207        CTCCAGACTGGCCCGGTAGTCAGGGGCTCAGGAGCAGATCCCGAGGCAGGCTTTGCTCAG 239 
BX419072        CTCCAGACTGGCCCGGTAGTCAGGGGCTCAGGAGCAGATCCCGAGGCAGGCTTTGCTCAG 240 
BX386531        CTCCAGACTGGCCCGGTAGTCAGGGGCTCAGGAGCAGATCCCGAGGCAGGCTTTGCTCAG 239 
BX432449        CTCCAGACTGGCCCGGTAGTCAGGGGCTCAGGAGCAGATCCCGAGGCAGGCTTTGCTCAG 239 
BX426875        CTCCAGACTGGCCCGGTAGTCAGGGGCTCAGGAGCAGATCCCGAGGCAGGCTTTGCTCAG 240 
BX328722        CTCCAGACTGGCCCGGTAGTCAGGGGCTCAGGAGCAGATCCCGAGGCAGGCTTTGCTCAG 239 
BX410653        CTCCAGACTGGCCCGGTAGTCAGGGGCTCAGGAGCAGATCCCGAGGCAGGCTTTGCTCAG 239 
BX410654        CTCCAGACTGGCCCGGTAGTCAGGGGCTCAGGAGCAGATCCCGAGGCAGGCTTTGCTCAG 239 
                ************************************** ********************* 
 
BX397992        CCTCCGACGAGGGCTGGCCCTTTGGAAGGCGCCTTCAACAGCCGGACCAGACAGGCCACC 299 
BX432450        CCTCCGACGAGGGCTGGCCCTTTGGAAGGCGCCTTCAACAGCCGGACCAGACAGGCCACC 299 
BX418456        CCTCCGACGAGGGCTGGCCCTTTGGAAGGCGCCTTCAACAGCCGGACCAGACAGGCCACC 299 
BX371207        CCTCCGACGAGGGCTGGCCCTTTGGAAGGCGCCTTCAACAGCCGGACCAGACAGGCCACC 299 
BX419072        CCTCCGACGAGGGCTGGCCCTTTGGAAGGCGCCTTCAACAGCCGGACCAAACAGGCCACC 300 
BX386531        CCTCCGACGAGGGCTGGCCCTTTGGAAGGCGCCTTCAACAGCCGGACCAGACAGGCCACC 299 
BX432449        CCTCCGACGAGGGCTGGCCCTTTGGAAGGCGCCTTCAACAGCCGGACCAGACAGGCCACC 299 
BX426875        CCTCCGACGAGGGCTGGCCCTTTGGAAGGCGCCTTCAACAGCCGGACCAGACAGGCCACC 300 
BX328722        CCTCCGACGAGGGCTGGCCCTTTGGAAGGCGCCTTCAACAGCCGGACCAGACAGGCCACC 299 
BX410653        CCTCCGACGAGGGCTGGCCCTTTGGAAGGCGCCTTCAACAGCCGGACCAGACAGGCCACC 299 
BX410654        CCTCCGACGAGGGCTGGCCCTTTGGAAGGCGCCTTCAACAGCCGGACCAGACAGGCCACC 299 
                ************************************************* ********** 
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Appendix S5. Translation of the Nucleotide Sequences of the ET 
Extensions 
 
Predicted ET part of H1.0  
 
 
ggatgctgggaaaagggaggcagaggaggcggaggcagaggcagaggcagagcccggtgccg 
   M  L  G  K  G  R  Q  R  R  R  R  Q  R  Q  R  Q  S  P  V  P  
agaccaagcgacagaccggcggggctgggcctcgcaaagccggctcggcgagctctcccg 
 R  P  S  D  R  P  A  G  L  G  L  A  K  P  A  R  R  A  L  P  
acacccgagccggggaggaaaagcagcgactcctcgctcgcatccccgggagccgcactc 
 T  P  E  P  G  R  K  S  S  D  S  S  L  A  S  P  G  A  A  L  
cagactggcccggtagtcaggggctcaggagcagatcccgaggcaggctttgctcagcct 
 Q  T  G  P  V  V  R  G  S  G  A  D  P  E  A  G  F  A  Q  P  
ccgacgagggctggccctttggaaggcgccttcaacagccggaccagacaggccaccatg… 
 P  T  R  A  G  P  L  E  G  A  F  N  S  R  T  R  Q  A  T  M  
 
 
Predicted ET part of HMGN1 
 
 
…gggatgctcgggcggcgggaggagtggcagcggcaaggcagcccagtttcgcgaaggctg 
  G  M  L  G  R  R  E  E  W  Q  R  Q  G  S  P  V  S  R  R  L  
tcggcgcgccgcggcccgcaggcacccggcacgcgccttccccgcaggcacccggcacgc 
 S  A  R  R  G  P  Q  A  P  G  T  R  L  P  R  R  H  P  A  R  
Gccttccccgccgccacgatg… 
 A  F  P  A  A  T  M 
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Appendix S6. Estimation of the ET-HMGN1 to HMGN1 Ratio in MCF7 
Cells 
  
Since the commercially available antibodies against HMGN1 recognize both “normal” 
and ET forms of the proteins (below, panel A), we were able to compare the levels of 
both protein forms on western blots. Series of dilutions of perchloric extracts from MCF7 
cells were western blotted and the staining intensities of HMGN1 and ET-HMGN1 were 
compared (below, panel B). The intensity of ET-HMGN1band in the undiluted sample 
(lane a) was similar to intensities of HMGN1 bands in 32-64 fold diluted sample (lanes f 
and g). Thus, we conclude that in MCF7 cells ET-HMGN1 occurs at levels of about 2-
3% of HMGN1.  
 
 
 
 
1    2    4    8   16  32  64 128 256
Dilution (fold)  
ET- HMGN1
HMGN1
 
 
 
 
 
 
 
 
A, Western blots of perchloric acid extracts of MCF7 cells probed with antibodies against 
ET-HMGN1 and HMGN1, respectively. B, Dilution series of the protein extracts probed 
with anti-HMGN1 antibodies.  
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Future directions 
 
It is my interest to further probe the function of the extended forms of nuclear proteins. The 
discovery of two ET-proteins implies the existence of a dedicated enzymatic machinery of RNA 
editing, which is probably used more widely. I would like to find possible specific binding 
partners of the ET part of H1.0 as well as to perform RNA pull-down experiments in order to 
identify potential components of the suggested RNA-editing machinery. Modern high resolution 
MS data may already contain many more examples of unexpected protein forms, which will 
surely be brought to light by thorough analysis.  
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CSF proteome and peptidome profiling 
 
Cerebrospinal fluid (CSF) is a liquid produced primarily by the choroid plexus epithelial cells. It 
provides brain and central nervous system (CNS) with nutrients, stimuli and protection. The 
blood-CSF barrier at the choroid plexus is formed between the epithelial cells which are linked 
by tight junctions and fenestrated blood capillaries. Cerebrospinal fluid continuously circulates 
through the ventricles, over the surface of the brain, and is absorbed at the arachnoid villi and at 
the cranial and spinal nerve root sheaths. CSF is produced at the rate of about 0.3 ml per min. 
Total CSF volume varies from 100 to 150 ml and its turnover rate is approximately 6 hours (75, 
76). For diagnostic purposes CSF is usually aspirated by lumbar puncture. CSF protein 
concentration is one of the most sensitive indicators of pathology within the CNS. Newborn 
patients have up to 150 mg per dL (1.5 g per L) of protein. The adult range of 18 to 58 mg per dL 
(0.18 to 0.58 g per L) is reached between six and 12 months of age (77).  
 
 
Figure  27.  The blood—CSF barrier. Choroid plexus epithelial cells are joined by tight 
junctions.  Microvilli are present on the CSF-facing surface of the choroid plexus cells increasing 
the surface area and aiding in fluid secretion. The molecules can permeate the barrier either 
passively or actively (from ref. (76) ). 
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Similar to blood, the prevalence of a small number of highly abundant proteins such as albumin, 
tranferrin or immunoglobulins makes the identification of the low abundant proteins in CSF very 
challenging. It is important to stress that CSF contains not only proteins but also neuropeptides 
which are shuttled by the CSF to their final destination targets. As a direct recipient of cell-
shedding products, it is a potential indicator of abnormal CNS states such as inflammation, 
infection, neurodegenerative processes, and tumor growth. Until recently, little was known about 
CSF polypeptide content. The rapid improvement of proteomics technologies presented 
researchers with opportunities to initiate CSF proteome profiling studies (78-82).  However, the 
number of publications pertaining to the CSF peptidome (i.e. endogenous peptides as opposed to 
proteins) remains very low. Our strategy was to perform a combined analysis of both proteome 
and peptidome CSF content of clinically normal patients and to create a depository of 
cerebrospinal fluid peptide and protein identifications so they can serve as a reference for future 
research. With our publication we also wanted to give an impulse to neural peptidome discovery 
studies. We used high accuracy and resolution mass spectrometry in both MS and MS/MS modes 
for characterization of the CSF peptidome content.  Endogenous peptides are often produced by 
non-typical enzyme cleavage. Thus, the database searches has to be performed with a “no 
enzyme specificity” option and the software processing time was significantly slower compared 
with the search when the enzyme cleavage site is known. Additionally, current software 
algorithms are not optimized for the “no enzyme specificity” search and do not fully utilize the 
high accuracy MS/MS data content provided by the advanced mass spectrometry 
instrumentation. Thus, we had to manually re-check the peptide identifications and de-novo 
sequence some of the post-translationally modified neuropeptides in order to modify the offset 
parameters of the search engine. Figure 28 presents some of the identified post-translationally 
modified peptides, the glycopeptides. 
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Figure 28. CSF glycopeptides identified by high accuracy MS/MS in this study. With the de-
novo sequencing identification of the DVSTPPTVLPDNFPRYPVGKF glycopeptide forms of 
IGF-II, the characteristic mass offsets of the discovered glycosylation signatures were taken into 
account while searching the protein database with MASCOT engine.  
 
We combined high accuracy and high resolution MS with low resolution MS/MS acquisition for 
proteome profiling. As the result of our work, 563 peptide forms and about 800 proteins were 
identified by high stringency criteria. This was the first integrated proteome/peptidome content 
analysis of any body fluid reported in the literature.  The study pointed out the potential of such 
analysis for CSF profiling and biomarker discovery. We showed that the major contributor to the 
protein population of CSF is protein secretion combined with ongoing proteolytic processes 
involved in cell surface remodeling and protein shedding. We also found, unexpectedly, that the 
CSF protein population differs in composition from that of plasma presumably due to functions 
of the CSF that are as yet mostly unexplored. This work also led to optimization of protocols for 
neuropeptide profiling and kindled our interest in identification and characterization of novel 
neuropeptides. 
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Integrated Analysis of the Cerebrospinal Fluid Peptidome and
Proteome
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Cerebrospinal fluid (CSF) is the only body fluid in direct contact with the brain and thus is a potential
source of biomarkers. Furthermore, CSF serves as a medium of endocrine signaling and contains a
multitude of regulatory peptides. A combined study of the peptidome and proteome of CSF or any
other body fluid has not been reported previously. We report confident identification in CSF of 563
peptide products derived from 91 precursor proteins as well as a high confidence CSF proteome of
798 proteins. For the CSF peptidome, we use high accuracy mass spectrometry (MS) for MS and MS/
MS modes, allowing unambiguous identification of neuropeptides. Combination of the peptidome and
proteome data suggests that enzymatic processing of membrane proteins causes release of their
extracellular parts into CSF. The CSF proteome has only partial overlap with the plasma proteome,
thus it is produced locally rather than deriving from plasma. Our work offers insights into CSF
composition and origin.
Keywords: cerebrospinal fluid • neuropeptides • LC-MS/MS • LTQ-Orbitrap • peptidomics • proteomics
Introduction
Cerebrospinal fluid (CSF) is produced mainly by the choroid
plexus in the lateral, third, and fourth ventricles of the brain
at an approximate rate of 500 mL per day in healthy adults,
the total volume of CSF being about 135 mL.1,2 With a turnover
time of about 6 h, CSF is in constant flow within the brain
ventricles and subarachnoid space of the brain and spinal cord,
providing buoyancy and protection. It carries nutrients for cells,
removes products of their metabolism, and serves as a transport
medium for hormones. It not only contains polypeptides which
pass through the blood-brain barrier but also harbors peptides
and proteins manufactured locally. As a direct recipient of cell-
shedding products, it is a potential indicator of abnormal CNS
states such as inflammation, infection, neurodegenerative
processes and tumor growth.
The low total protein concentrationsthe CSF/serum ratio
of protein concentration is about 0.004sas well as high
amounts of albumin and immunoglobins (about 70%)3 chal-
lenge the identification of low-abundant proteins in CSF by
2D electrophoresis and make liquid chromatography–mass
spectrometry-based technologies4 the method of choice for CSF
proteome profiling. Additionally, the resolution of electro-
phoresis-based methods is low for polypeptides smaller than
10 kDa, which makes ultrafiltration or precipitation combined
with mass spectrometry practically the only option for low
molecular weight proteome or “peptidome” profiling.5
CSF has been the subject of several proteomic studies during
recent years. Published reports concentrated on discovering
potential CSF biomarkers in neurodegenerative diseases,6–8
multiple sclerosis,9 traumatic brain injury,10,11 and aging12 as
well as on the analysis of a broad inventory of CSF proteins.13–16
In contrast to CSF proteome studies, the number of publica-
tions related to the CSF peptidome is scarcesdespite the
tremendous interest in finding novel ligands for orphan recep-
tors, particularly the GPCRs, the treasure trove of the pharma-
ceutical industry. Stark et al.17 were the first to use organic
phase extraction and mass spectrometry-based profiling to
identify a number of peptides in human CSF. Yuan and
Desiderio18 employed ultrafiltration and mass spectrometry in
a proof-of-principle CSF peptidomics study. Not much has
been added to this knowledge afterward, notwithstanding the
ongoing dramatic improvements in mass spectrometric and
separation technologies.
Here we present the first in-depth and high-confidence study
of the CSF peptidome, consisting of 563 identified peptides
derived from 91 protein precursors in cerebrospinal fluid. We
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also report the detection of 798 proteins in a parallel proteome
profiling study by one-dimensional gel enhanced liquid chro-
matography–mass spectrometry (GeLC-MS). Some of the
identified neuropeptides were found to carry features typical
of regulatory peptides such as evidence that they were pro-
duced by proconvertase cleavage, N-terminal pyroglutamina-
tion, C-terminal amidation, and high cysteine content. Fur-
thermore, half of their precursor proteins, including the
precursors of known neuropeptides, were not identified in the
proteome mapping experiment, suggesting that they are func-
tional and not mere degradation products of abundant CSF
proteins. Our high-confidence CSF proteome indicates that
secreted and membrane bound proteins are by far the largest
contributors. Interestingly, the CSF proteome is enriched in the
membrane-bound receptor tyrosine phosphatase (PTPR) fam-
ily, including the potential remyelination marker PTPRZ.
Our study was designed to give an impulse to the nascent
CSF peptidome field and also to create a depository of
cerebrospinal fluid peptides and proteins so they can serve as
a reference for future research.
Experimental Details
Sample Collection and SDS-PAGE. CSF samples were taken
by lumbar puncture for diagnostic purposes that turned out
to be normal by standard clinical chemistry analysis. The study
was approved by the ethical committee of the chamber of
physicians in Hamburg and by the local ethics committee of
the University of Jena. The samples were obtained by a
pneumatic tube approximately 30–60 min after the CSF tap.
Then aliquots were taken for clinical chemistry, and the CSF
cytology was performed. The specimens were barcoded and
frozen immediately after clinical laboratory analysis at -80 °C.
These are the usual conditions for CSF analysis in a routine
clinical setting. The total protein concentration, albumin, IgG,
IgA, and IgM concentrations, the CSF/serum albumin ratio, and
the IgG/albumin index revealed no signs of inflammation,
blood-brain barrier leakage, or intrathecal IgG synthesis.19,20
The CSF cell counts were within the reference range.21 These
samples are representative of a typical patient without CNS
inflammation, e.g., for a “diagnostically normal individual”.
Additional assessment of the five samples in the pooled
fraction for the presence of hemoglobin by a human hemo-
globin ELISA (Immundiagnostik AG; Bensheim, Germany)
revealed no signs of blood contamination. The samples were
consecutively reduced with dithiothreitol and alkylated by
iodoacetamide before ultrafiltration. To collect the low molec-
ular weight range fractions and to concentrate proteins, the
samples were subjected to ultrafiltration on Centricon filter
devices with a cutoff of 10 kDa (Millipore, Bedford, MA). Protein
portions from the CSF samples of five individuals (0.5 mL of
CSF each) were pooled; a protein portion of a sample from one
individual, originating from 2 mL of CSF, was analyzed
separately. Six ultrafiltrate low molecular weight fractions from
the above-mentioned individuals were also analyzed separately.
Proteins were resolved on 4–12% gradient NuPAGE Novex
Bis-Tris gels (Invitrogen, Carlsbad, CA). The lanes were cut
into 11 or 10 pieces and subjected to a standard in-gel trypsin
digestion protocol. Briefly, the pieces were washed twice with
25 mM ammonium bicarbonate (ABC)/50% ethanol and de-
hydrated with absolute ethanol. After that, 0.5 µg of trypsin
(Promega, Madison, WI) solution in 25 mM ammonium
bicarbonate was added, and the enzyme was allowed to digest
overnight at 37 °C. The peptide mixtures were extracted with
50% acetonitrile and 2% trifluoroacetic acid (TFA), and the
organic solvent was evaporated in a vacuum centrifuge.
Samples were reconstituted with 1% TFA, and STAGE tip
purification was performed as previously described.22
The ultrafiltrate low molecular weight fractions were dried
down in a vacuum centrifuge to a final volume of about 40 µL.
An equal volume of 2% TFA was added, and the STAGE tip
purification was performed.
LC-MS/MS and Data Analysis. Peptide mixtures were sepa-
rated by online reversed-phase nanoscale capillary liquid
chromatography (LC) and analyzed by electrospray tandem
mass spectrometry. The samples were injected onto an in-
house made 15 cm reversed-phase fused silica capillary column
emitter (inner diameter 75 µm, packed with 3 µm ReproSil-
Pur C18-AQ media (Dr. Maisch GmbH, Ammerbuch-Entringen,
Germany)), using an Agilent 1100 nanoflow system (Agilent
Technologies, Palo Alto, CA). The LC setup was connected to
either a linear quadrupole ion trap-orbitrap (LTQ-orbitrap) or
a linear quadrupole ion trap-Fourier transform (LTQ-FT) mass
spectrometer (Thermo Electron, Bremen, Germany) equipped
with a nanoelectrospray ion source (Proxeon Biosystems,
Odense, Denmark).
In the case of proteome mapping using the LTQ-Orbitrap,
the mass spectrometer was operated in the data dependent
mode. Survey full scan MS spectra (fromm/z 300 to 1600) were
acquired in the orbitrap with resolution R ) 60 000 at m/z 400
(after accumulation to a target value of 1 000 000). The five or
ten most intense ions were sequentially isolated for fragmenta-
tion and detection in the linear ion trap using collisionally
induced dissociation at a target value of 30 000. Target ions
already selected for MS/MS were dynamically excluded for 45 s.
In the case of proteome mapping on the LTQ-FT, the mass
spectrometer was operated in the data-dependent mode to
automatically switch between MS, MS2, and MS3 acquisition.
Survey spectra in an m/z range of 300–1575 were acquired by
FT-ICR, and the three most intense ions in them/z ratio range
450–1400 were sequentially chosen for accurate mass measure-
ment by FT-ICR-selected ion monitoring (SIM). They were
subsequently fragmented in the ion trap to obtain MS2 spectra.
The most intense ion in MS2 spectra was selected for another
round of collisionally induced dissociation to obtain MS3
spectra. The other MS conditions were the same as described
previously.
For peptidome profiling on the LTQ-Orbitrap, survey full
scan mass spectra (from m/z 300 to 2000) were acquired in
the orbitrap after accumulation to a target value of 1 000 000
with resolution R ) 60 000. The five most intense ions were
fragmented either in the ion trap or in the C-trap (Higher-
energy C-trap dissociation, HCD). The MS/MS products were
measured in the orbitrap with the resolution value set to 15 000
(after accumulation to a target value of 100 000). For accurate
parent mass measurements, the lock-mass option was used as
previously described.23 Target ions already selected for MS/
MS were dynamically excluded for 30 s.
The acquired data were searched against an in-house curated
International Protein Index human protein sequence data-
base24 (IPI 3.17) with an automated database searching pro-
gram, MASCOT (Matrix Science, London).25 For proteome
profiling, spectra were searched allowing a maximum mass
deviation of 10 ppm and 0.4 Da for MS and MSn peaks,
respectively. MS3 spectra were automatically scored with
MSQuant, an open source program developed in-house (http://
msquant.sourceforge.net) which parses MASCOT peptide iden-
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tifications and enables their manual and automated validation.
For peptidome profiling, spectra were searched with a maxi-
mum mass deviation of 10 ppm and 0.01 Da for MS and MS2
peaks, respectively. All relevant hits were manually verified
according to the following rules: (1) to be accepted for manual
validation, the peptides needed to be at least seven amino acids
in length and have a minimum MASCOT score of 15 (note that
the mass accuracies in MS and MS/MS modes were extremely
high and that MASCOT does not increase its score for high mass
accuracy in MS and MS/MS data); (2) the majority of the most
intense MS/MS ions should belong either to the y and b
products of the precursor peptide or have a relevant link to
these products, e.g., loss of H2O from an ion containing a serine
residue; (3) presence of the b2 and a2 ions; (4) if present, the y
ion originating from the fragmentation at the proline residue
and the corresponding b ion should have increased intensity;
(5) continuity of the ion series (if discontinuous, a special
explanation is required, e.g., the presence of the proline
residue). An introduction to the rules of MS/MS sequencing
can be found in the tutorial by Steen and Mann.26 Some of
the glycopeptides were partially sequenced de novo. With their
sugar signatures revealed, the corresponding δ masses of the
modifications were used in subsequent MASCOT searches.
To prepare our protein list, the peptide identifications were
subjected to very stringent filtering. Only peptides with seven
amino acids or longer were accepted. All of them were required
to score above 27, a score indicated by MASCOT to be
significant (p < 0.05). Proteins identified with at least two
peptides were accepted. For one peptide hit identifications, in
the case of LTQ-FT analysis, corresponding MS3 validated
spectra were required for positive identification. We ran a
search against an IPI decoy database containing both forward
and reversed sequences to estimate the number of false positive
identifications present in the sample. Applying the same
stringent criteria as we did for the forward database, searches
of the reversed sequences resulted in no positive hits, confirm-
ing the reliability of our identifications.
Bioinformatics Analysis. For bioinformatics analysis, the
ProteinCenter software package (Proxeon Bioinformatics A/S,
Odense, Denmark) was used. ProteinCenter integrates public
sequence databases to form a comprehensive and consistent
superset. Due to support of major protein sequence databases
and computational enrichment, ProteinCenter decreases the
redundancy of the databases and significantly improves protein
annotation. Signal peptide and transmembrane region predic-
tions were automatically calculated by the software package.
Gene Ontology distributions were calculated based on the GO
Slim categories (http://www.geneontology.org/GO.slims.html)
that give a broad overview of the ontology content. Filtering
on peptidase activity was performed according to enzyme
nomenclature EC 3.4. For the fold change analysis of GO
categories, we used BiNGO, a Cytoscape plug-in27 to find
statistically over-represented GO categories in our CSF pro-
teome map, taking as a reference the whole human proteome.
A custom GO annotation for the reference IPI human data set
was created by extracting GO annotations available for Human
IPI IDs from EBI GOA Human 39.0 release (28 873 protein
annotations).28 The analysis was done using the “HyperGeo-
metric test”, and all GO terms which were significant with p <
0.001, after correcting for multiple term testing by Benjamini
& Hochberg False Discovery Rate corrections, were selected as
overrepresented.29
Results and Discussion
The samples were obtained by lumbar puncture from six
individuals undergoing diagnostic investigation. Typically 0.5
mL of CSF sample was available for analysis, which considering
the low concentration of proteins in CSF made this investigation
challenging in terms of sensitivity. By means of ultrafiltration,
the CSF samples were split into low molecular “peptidome”
and higher molecular “proteome” fractions (Figure 1). The
peptidome fractions were analyzed directly, by capillary liquid
chromatography and high accuracy mass spectrometric acqui-
sition on LTQ-Orbitrap in both MS and MS/MS modes using
different and complementary fragmentation modes.
For the CSF proteome study, we analyzed a 2 mL sample
from one individual as well as the pooled higher molecular
weight fraction of the 0.5 mL samples of five individuals. The
large dynamic range of protein concentrations, where the
overwhelming presence of a few proteins overshadows the rest,
makes cerebrospinal fluid an analytic challenge similar to
plasma. For example, the proportion of albumin and immu-
noglobulins can be as high as 65–70% of the total CSF protein
content, creating difficulties in identification of the less-
abundant proteins. As we have shown in previous studies, one-
dimensional SDS-PAGE separation combined with tryptic
digestion of the excised bands and subsequent LC-MS runs can
successfully analyze the proteome to considerable depth.30 We
separated the CSF proteomes using 1D gels and analyzed them
by LC MS/MS. The final CSF protein data set was derived by
extensive protein profiling of the single CSF sample combined
with the analysis of the pooled CSF samples. An overview of
the experimental workflow is presented in Figure 1.
CSF Peptidome. In conventional proteome mapping experi-
ments, proteins are digested with trypsin, and each protein is
usually identified by at least two fully tryptic and nonmodified
peptides. Tryptic peptides carry C-terminal basic amino acids
protonated under acidic conditions facilitating their mass
spectrometric fragmentation and consequent interpretation of
the data. The identification of neuropeptides is much more
challenging. They do not terminate in predictable amino acids,
making the number of candidates to be considered in the
database search much higher, and the nonstandard charge
distribution within the peptide sequence can produce frag-
mentation spectra with a smaller number of characteristic ions.
Most importantly, neuropeptides can be post-translationally
modified, additionally complicating their analysis. To address
these challenges, we employed a hybrid mass spectrometers
the LTQ-orbitrapscapable of high-resolution, high-accuracy
analysis in the orbitrap part of the instrument and analyzed
both the peptides and their fragmentation products in the
Figure 1. Overview of the procedure used for the analysis of the
CSF peptidome and proteome.
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orbitrap. Additionally, we utilized a novel fragmentation method
termed higher-energy C-trap dissociation (HCD) for MS/MS.31
This allowed us to observe the full mass range of fragments in
the spectra, facilitating the identification of peptides by adding
the information of characteristic low mass ions such as y1, y2,
a2, b2, and reporter ions of post-translational modifications.
This contrasts with the normal mode of operation of ion traps
in which fragment spectra are obtained at low resolution in
the ion trap part of the instrument and with a low mass cutoff
at about one-third of the precursor mass to charge (m/z) ratio.
In this way, from the six individuals, 563 peptides, including
known neuropeptides, originating from 91 protein precursors
were identified with extremely high stringency and manual
verification (Supporting Information Table 1). The fact that
several hundred neuropeptides can be identified at high
stringency from a small volume clinical sample implies both
high analytical sensitivity of our methods and rich peptide
content of CSF. We first analyzed broad features of the CSF
peptidome. A remarkable trait of the identified precursor
proteins is that 78 of them (84%) are predicted to contain a
signal peptide sequencesone of the features of secreted
proteins in general and prepro-hormones in particular. A total
of 46 precursor proteins (Supporting Information Table 2) did
not appear in our CSF proteome data set, and some of these
proteins are known precursors of neuropeptides. During a
typical hormone processing event, the signal peptide is re-
moved from a prepro-hormone by a signal peptidase.32 The
pro-hormone can be cleaved by specific convertases at dibasic
sites, generating precursors which then are acted upon by
carboxypeptidases33 giving rise to mature forms of peptide
hormones. In addition to this, peptides can become C-
terminally amidated by peptidylglycine monooxigenase which
requires a C-terminal glycine in the peptide sequence.34 For
some of the peptides, for example, the corticotropin-releasing
hormone, the amidation is crucial for receptor binding.35 In
our data set, 23 of the identified peptides were produced by a
typical dibasic cleavagesmeaning a dibasic site N-terminal and
C-terminal to the peptide or a signal peptide site N-terminal
and a dibasic site C-terminal to the peptide. These included
the proteolysis products of proSAAS and 7B2 proteins, the
inhibitors of the most well-known pro-hormone convertases
PC1 and PC2, respectively36 (Supporting Information Table 3).
Pyroglutamic acid can be an essential element in functioning
of biologically active peptides.37 Hinkle et al.,38 for example,
demonstrated its importance in thyrotropin-releasing hormone
receptor binding. Of the identified peptides, we found that 53
carry pyroglutamate at the N-terminus, which made this the
most abundant modification in our data set. It should be
stressed, though, that the majority of the pyroglutamate
modifications of N-termini of peptides observed in proteomics
experiments is introduced during the sample preparation
process. Thus, it is impossible to suggest a functional meaning
of a neuropeptide carrying solely N-terminal pyroglutamate
without any other characteristic neuropeptide features.
Many biologically active peptides, such as insulin or endot-
helin, contain disulfide bridges which not only determine the
functional structure of the molecules but also often protect
them from proteolysis.39,40 Additionally, some of the antimi-
crobial endogenous peptides, defensins, are disulfide bonded
into specific structures.41 We identified a set of cysteine-
containing peptides, usually with an even number of cysteine
residues. In some cases, peptides also contained an odd
number of cysteine residues, the “spare” or sole cysteine
residue functioning, presumably, in homodimerization.
The γ-secretase complex cleaves type I membrane proteins
within their transmembrane domains.42 Specifically, γ-secre-
tase releases the amyloid  peptide (A) that accumulates in
the brains of patients with Alzheimer’s disease.43 Our data
contain a number of possible secretase-related peptide prod-
ucts that in addition to being derived mostly from type I
membrane proteins also reveal the characteristic secretase
intramembrane cleavage signature at their C-termini (Support-
ing Information Table 4). Some of the peptides were found to
be post-translationally modified by sulfation, phosphorylation,
and O-linked glycosylation, the sialylated sugar adduct being
HexNAcHex(NeuAc)(1–2). Representative peptides containing
one or more of the above-mentioned features are discussed in
the following. For each of these representatives, we provide
an overview of what is known from the literature as well as
which novel instances of these classes we discovered in our
CSF peptidome study.
1. Joining peptide (JP) of the corticotropin-lipotropin (pro-
opiomelanocortin, POMC) precursor is a 30-amino-acid peptide
located between the melanotropin γ and adrenocorticotropic
hormone (ACTH) parts of the POMC precursor.44,45 After
cleavage at dibasic residues by proconvertases, C-terminal basic
groups are removed by carboxypeptidase, and the glycine
residue is acted upon by R-amidating monooxygenase, gener-
ating the C-terminally amidated peptide (Figure 2a). It was
shown previously that JP is secreted as a homodimer through
disulfide bonding between the single cysteine residues.44
Illustrating how our technology can identify known neuropep-
tides in CSF, Figure 2b shows a representative MS/MS spectrum
of the identified JP of POMC. The protein from which this
peptide is derived, the corticotropin-lipotropin precursor, was
not identified in the proteome profiling part of our work. This
is as expected because it is being processed into different
neuropeptides.
2. Neurexophilins are suggested to act as neuropeptides
interacting with neurexins, a large family of neuronal cell
surface proteins believed to be involved in intercellular signal-
ing and formation of intercellular junctions.46 We identified two
novel peptide products derived from neurexophilin-3 and
neurexophilin-4. Figure 3a shows the neurexophilin-3-origi-
nating peptide produced by removal of the signal peptide from
the precursor and by proconvertase/carboxypeptidase action
at the dibasic site. Mass spectrometry shows that the N-
terminal glutamine of the peptide is converted into pyro-
glutamate. The conspicuous proline occurrence preceding and
trailing basic residues probably not only influences peptide
structure but also shields it from proteases.47 Peptide sequence
alignment shows a high level of conservation in mammals,
including the signal peptide and dibasic cleavage sites, N-
terminal glutamine, as well as the positioning of multiple
proline residues (Figure 3b). Neurexophilins were not present
in our CSF proteome map.
3. Synaptotagmins are believed to mediate calcium-depend-
ent regulation of membrane trafficking. Only synaptotagmin-1
has been characterized in detail, and the functions of other
members of the family are unclear.48 We identified novel
peptides derived from synaptotagmin-11, synaptotagmin-7, and
synaptotagmin-4 as possible γ-secretase-cleavage products.
Synaptotagmins were not identified in our CSF proteome
profiling experiment. Figure 4a shows the synaptotagmin-11-
derived peptide. The MS results reveal that the N-terminal
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methionine of the precursor is removed and that alanine-2 is
acetylated. Synaptotagmin-11 has a single-path transmembrane
domain spanning residues 16–36. We find that γ-secretase cuts
the precursor within the transmembrane domain at leucine-
20, and glycine-19 is acted upon by R-amidating monooxyge-
nase generating the C-terminally amidated peptide.
4. FXYD family members are single-span membrane proteins
considered to either be regulators of ion channels or function
as ion channels themselves.49 We found peptides derived from
FXYD-6 and FXYD-1 (phospholemman). Phospholemman is
Figure 2. Joining peptide (JP) of pro-opiomelanocortin (POMC). (a) Suggested processing events leading to the formation of JP. (b) An
example of the MS/MS fragmentation spectrum of the amidated EDVSAGEDCGPLPEGGPEPRSDGAKPGPRE-NH2 peptide product (JP)
of POMC. N-Terminal fragments (B-ions) and C-terminal fragments (Y-ions) are labeled. See ref 26 for an introduction to peptide
sequencing. The charge states of multiply charged fragments are indicated by “plus” signs, and mass differences to calculated values
are indicated in parentheses.
Figure 3. Neurexophilin-3-originating peptide. (a) Suggested
processing events leading to the formation of the neurexophilin-
3-derived peptide. (b) The alignment of the peptide sequence
shows a high level of conservation of its sequence in mammals.
Residues in red highlight differences from the human sequence.
Figure 4. Possible processing events leading to the formation
of the peptide derived from (a) synaptotagmin-11 and (b)
phospholemman.
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highly expressed in the CNS. It is most abundant in the
cerebellum and Purkinje neurons and also enriched in choroid
plexus.50 Here we find that phospholemman is cleaved by
γ-secretase or a similar enzyme. Figure 4b shows a phosp-
holemman-derived peptide produced by removal of the signal
sequence from the precursor and γ-secretase cleavage at
isoleucine-46 within the transmembrane domain of phosp-
holemman (residues 36-56). MS and MS/MS data show that
the peptide is C-terminally amidated, indicating that glycine-
45 is acted upon by R-amidating monooxygenase. FXYD
proteins do not appear in our CSF proteome data set.
5. Granulins are cysteine-rich peptides which can modulate
the growth of epithelial and mesenchymal cells in vitro. They
are believed to be potential growth factors derived from the
precursor glycoprotein and contain seven tandem repeats of
the 12-cysteine granulin domain.51 We identified one member
of the family, a paragranulin-like peptide. This peptide, pro-
duced by action of signal peptidase at the N-terminus and an
unknown enzyme at leucine-45 of the granulins precursor,
spans residues 18-44. The C-terminal proline-44 directly
preceding the basic arginine residues probably acts as a
protection against protease cleavage. Paragranulin contains six
cysteine residues likely used in intramolecular disulfide bond
formation (Figure 5a). As an example of cysteine-containing
peptides, Figure 5b presents an MS/MS spectrum of the
paragranulin-like peptide. The granulin precursor protein was
not identified in our CSF proteome profiling experiment.
6. Insulin-like growth factor-2 (IGF-2) is expressed in most
embryonic tissues. After birth, IGF-2 expression ceases in some
tissues, but the gene is often reactivated during tumorigen-
esis.52 While the mature forms of insulin-like growth factors
are structurally similar to insulin,53 their functions and bio-
genesis are not completely understood. The production of
IGF-2 involves removal of the signal peptide from the precursor
followed by release of the mature 67-amino-acid peptide IGF-2
as well as the 89-amino-acid C-terminal E-peptide. The role
of the E-peptide derived from pro-IGF-2 is unclear; however,
the analogous E-peptide of pro-IGF1, another member of the
IGF family, possesses mitogenic activity.54 Here we identified,
for the first time, glycosylated forms of peptides covering the
first 21 residues of the E-peptide, as well as unmodified
peptides originating from its middle part. IGF-2 peptides
secreted by transfected HEK 293 cells contain significant
amounts of sialic acid. The O-linked glycosylation sites of this
overexpressed construct were mapped.52
O-Linked sugars are very labile and tend to “fall off” the
peptide and “disappear” during the mass spectrometric frag-
mentation event. In the HCD fragmentation mode used here,
an excess of the collision energy (CE, the potential difference
with which the peptides are injected into the C-trap) leads to
characteristic low mass ions (oxonium ions for sugars) as well
as to peptide sequence specific ions, but information about
the attachment site is lost. Figure 6 presents a fragmentation
spectrum of a representative glycosylated peptide product of
pro-IGF2. This peptide, with sequence DVSTPPTVLPDNF-
PRYPVGKF, is modified by O-linked glycosylation at the known
site, threonine-99, carrying the HexNAcHex(NeuAc)2 sugar.
When the HCD fragmentation spectrum of the pro-IGF2-
derived peptide was acquired with the CE value of 50, we
observe a singly charged ion at m/z 274.092 corresponding to
the dehydrated oxonium ion of sialic acid. We can also clearly
follow the y-ion series, and taking into account the presence
of the reporter ion indicating a possible sugar attachment, we
identified the peptide (Figure 6). However, for the reasons
Figure 5. Paragranulin-like peptide. (a) Suggested processing events leading to the formation of the paragranulin-like peptide. (b) An
example of the MS/MS fragmentation spectrum of the RCPDGQFCPVACCLDPGGASYSCCRP paragranulin-like peptide.
CSF Peptidome and Proteome Characterization research articles
Journal of Proteome Research • Vol. 7, No. 01, 2008 391
74
noted above, the exact location of the modification, as well as
its structure, is not apparent from this spectrum. We found that
by lowering the CE from 50 to 35 we did observe fragment ions
bearing sugar attachments (Figure 7). In this case, the sugars
are partially preserved enabling us not only to pinpoint the
O-linkage site but also to deduce the tentative glycosylation
structure, even though the fragmentation of the peptide
backbone does not yield many characteristic ions. Based on
this identification of a glycopeptide, we modified the search
engine to take the characteristic mass offsets due to glycosy-
lation into account. The characteristic dehydration product of
the sialic acid oxonium ion was then used to help verify the
proposed identifications. In this way, we found fractalkine,
SEL-OB, and Cadherin-20, solely as their glycosylated forms.
We also identified the glycosylated peptide products of the
heparin-binding EGF-like growth factor, which is discussed
next.
7. Heparin-binding EGF-like growth factor (HB-EGF) pre-
cursor is a single-path transmembrane protein, containing a
signal peptide, N-terminal pro-region, the actual HB-EGF
Figure 6. HCD fragmentation spectrum of the representative glycosylated DVSTPPTVLPDNFPRYPVGKF (O-linked HexNAc1Hex1NeuAc2)
peptide product of pro-IGF2 acquired with the CE value of 50.
Figure 7. HCD fragmentation spectrum of the representative glycosylated DVSTPPTVLPDNFPRYPVGKF (O-linked HexNAc1Hex1NeuAc2)
peptide product of pro-IGF2 acquired with the CE value of 35.
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(comprised of heparin-binding and EGF-like domains, residues
63-148), juxtamembrane, transmembrane, and a short cyto-
plasmic part. HB-EGF binds to EGFR (ErbB1) and ErbB4
receptors and is mitogenic to fibroblasts and smooth muscle
cells.55,56 Even though the physiological role of HB-EGF is
unclear, HB-EGF expression is essential for tumor formation
in cancer-derived cell lines.56 At least two O-linked glycosyla-
tion sites of HB-EGF are known.55 We identified a novel
glycosylated peptide derived from the N-terminal pro-region
of the HB-EGF precursor. The peptide spans residues 32-61
and is produced by the action of carboxypeptidase and pro-
convertase enzymes (Figure 8a). We were not able to unequivo-
cally pinpoint the site of glycosylation, but according to our
MS/MS data (not shown), the HexNAc1Hex1NeuAc1 sugar is
attached to one of three residues: threonine-44, serine-46, or
threonine-47.
8. Orexin-A and orexin-B (hypocretins) are a family of
neuropeptide ligands for orexin GPCRs identified and named
independently by two groups.57,58 The peptide sequences are
highly conserved in mammals. Their production takes place
exclusively in the lateral hypothalamus, the area thought to be
responsible for food intake. Nevertheless, the major known
lesion associated with the malfunctioning of the orexin system
is narcolepsy, a human sleep disorder caused by failure of
orexin signaling due to impaired trafficking and processing of
the precursor polypeptide.59 Interestingly, while the orexin-A
neuropeptide (residues 34–66 in the preprotein) has two
disulfide bonds (Cys39-Cys45, Cys40-Cys47), there are no
cysteine moieties in the orexin-B sequence (residues 70–97 in
the preprotein). This implies different 3D structures and
interaction profiles. Indeed, the orexin-1 receptor has signifi-
cantly stronger affinity for orexin-A, whereas the orexin-2
receptor binds both neuropeptides with similar affinity.59 In
this work, we identified two cysteine-containing peptide vari-
ants (residues 34–47 and 34–49) derived from the N-terminal
part of orexin-A (Figure 8b). Both peptides are produced by
signal peptidase action on the N-terminal part of the precursor
protein. MS shows that the N-terminal glutamine of the
peptides is transformed into pyroglutamic acid. The origin of
enzymes participating in the C-terminal cleavages is unclear.
The quadruple cysteine structure is preserved in both peptides.
Apart from the examples given above, our CSF peptidome
data contain a wealth of other information on potential
regulatory neuropeptides as well as unexpected findings such
as a number of polyproline peptides of unknown origin
containing 7-12 proline residues. To facilitate use of the data
by the community, we have made the CSF peptidome available
as part of the MAPU database.
CSF Proteome. As mentioned above, our CSF proteome
study utilized samples from six individuals, of which one was
profiled independently and the other five were profiled as a
pooled sample. For the profiling of the individual sample, we
used methods similar to those in our previous seminal, tear
fluid, and urinary proteome studies.60–62 In particular, two
consecutive stages of fragmentation were employed on a linear
ion trap Fourier transform instrument (LTQ-FT) to essentially
eliminate all false positive identifications.63 The pooled sample
was analyzed with the LTQ-Orbitrap, again requiring extremely
stringent identification criteria with at least two peptides
required for positive protein validation. A reverse database
search indicates that using the employed criteria our CSF
proteome should not contain any false positive protein iden-
tifications (see Methods). To combine the proteome profiling
experiments and to analyze the data, we used the ProteinCenter
software (www.proxeon.com). The overall features of our CSF
proteome map (Supporting Information Table 5) were further-
more classified using Gene Ontology (GO)64,65 for protein
categorization (see Methods and Supporting Information
Figure 1).
We first compared the proteome features between single (657
identified proteins) and pooled (531 identified proteins) samples
to make sure that individual sample variability had no influence
on the general proteome profile. As shown in Figure 9, the
proportions of characteristic features such as the number of
membrane and extracellular proteins, proteins engaged in
signal transduction, and receptor activity as well as proteins
with a predicted signal sequence are very similar between the
two data sets. From this, we conclude that our sample of six
individuals is representative of the CSF proteome. GO analysis
of our CSF proteome shows that by far the major predicted
cellular localizations are membrane and extracellular (44 and
38%, respectively; note that proteins can have several GO
localizations). There are few proteins with annotated intracel-
lular localizations; for example, Golgi, cytosol, and nuclear
categories account for less than 4% each. Additionally, the
proportion of proteins predicted by the SignalP algorithm to
carry signal peptides was 74%, whereas it is only 15% for the
proteome as a whole. While largely expected, these findings
support the high quality of the CSF preparation and analysis.
GO functional analysis revealed a striking proportion of pro-
teins involved in signal transducer and receptor activities (25
and 17%, respectively). We next determined the overlap
between our CSF proteome map and the recently published
CSF proteome data set of Abdi et al.8 From that data set, we
extracted proteins identified with at least two peptides. With
the aid of ProteinCenter, proteins in both data sets were
clustered at the 98% homology level to group alleles of the same
proteins with fragments and to remove redundancy in protein
sequences. Additionally, keratin identifications were filtered
out. The overlap between our data set (767 proteins) and the
CSF data set of Abdi et al. (650 proteins) was close to 40%. This
overlap is reasonable, in our opinion, as different methodolo-
gies were employed and as neither CSF proteome is exhaustive
at this stage. We further compared our proteome to the recently
published CSF data set of Pan et al.66 That CSF proteome was
created by the combination of a large number of CSF studies
Figure 8. Suggested processing events leading to the formation
of the peptides derived from (a) heparin-binding EGF-like growth
factor and (b) orexin-A.
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using different methodologies. We found 75% overlap of our
data with theirs at the 98% homology level.
Comparison of the CSF Proteome with the Human
Plasma Proteome. Cerebrospinal fluid and plasma are special-
ized body fluids bridged at the choroid plexus. Plasma proteins
enter CSF by a simple diffusion-based mechanism as a function
of their molecular size across the blood-brain barrier. It is
generally believed that the majority of proteins in CSF originate
from blood.67 We compared our data with the published
Human Proteome Organization (HUPO) high-confidence plasma
proteome data set of 889 proteins68 using similar methodology
as described above. We found that 581 proteins were unique
to our CSF data set (76% of the CSF proteome). When
comparing the identified proteins in each study for their GO
cellular compartment annotation, we found that extracellular
and membrane-bound proteins were much more abundant in
the CSF proteome than in the HUPO plasma proteome (Figure
9a). We subtracted the HUPO plasma proteome from our data
set, creating a CSF “unique” proteome. Note that the plasma
proteome is currently incomplete and that further quantitative
studies would be necessary to define truly unique CSF proteins.
Interestingly, the portion of membrane-bound and extracellular
proteins was similar between plasma and “CSF unique” pro-
teomes (23% and 26%, respectively), whereas the CSF unique
proteome has more than twice the proportion of membrane-
bound proteins (Figure 9a). Remarkably, about 74% of all CSF
proteins have a predicted signal peptide sequence, while only
32% of the HUPO plasma proteins do (Figure 9c). Similarly,
the proportion of proteins annotated for signal transduction
and for receptor activity was much higher in CSF than in
plasma (26% vs 13% and 17% vs 8%, respectively; see Figure
9b). Supporting the findings from our CSF proteome study, we
found that the overlap of the Abdi et al. CSF data set with the
HUPO plasma proteome was similar (21% vs 24% in our data
set; Supporting Information Figure 3). Based on this observa-
tion, we conclude that even though a significant share of
proteins in CSF appears to originate from plasma, the intrinsic
CSF proteins constitute the major part of its proteome, at least
at the level detected by current proteome profiling technologies.
Origin of Membrane Proteins in CSF. The most outstanding
feature of the CSF proteome is the prevalence of membrane-
bound proteins. The CSF peptidome analysis described above
provides at least a partial explanation of this finding. It is well-
known that proteolysis is responsible not only for remodeling
of the cell surface but also for release of some of the membrane-
bound proteins from their anchor.69,70 Based on our observa-
tion of the cleavage sites of neuropeptides and the extracellular
parts of the corresponding proteins (see below), we suggest that
a number of the identified membrane-bound proteins are
proteolytically cleaved in the membrane vicinity and their
extracellular parts are released into the surroundings. The
situation appears to be different from that in the urinary
proteome where we observed peptides from the full lengths of
the proteins60 and where secretion in exosomes has been
proposed to be the major process responsible for the presence
of membrane proteins in this body fluid. Below we discuss
several specific examples of the proposed proteolytic mechanism.
1. Amyloid precursor-like protein 1 (APLP1), -amyloid
precursor protein (APP), and amyloid precursor-like protein 2
(APLP2) belong to a family of type I membrane proteins. All
three proteins are closely related and are subject to site-specific
proteolysis by secretases.71,72 Even though the exact function
of APLP1 is unknown, recent studies have shown that it
modulates endocytosis and proteolytic processing of APP.73 A
possible role of APLP1 in regulation of R2A-adrenergic receptor
trafficking has also been proposed.74 The sequence of APLP1
is comprised of a signal peptide (residues 1–38), an extracellular
part (residues 39–650), a membrane part (residues 581–603),
and a short C-terminal cytoplasmic part (residues 604–650).
We identified the extracellular part of APLP1 during our CSF
Figure 9. Comparison of our CSF proteome with the HUPO
plasma data set published by States et al. (a) GO annotation of
membrane and extracellular localizations for the in-depth CSF
proteome of one individual, the pooled CSF proteome of five
individuals, the proteome obtained by subtraction of the HUPO
plasma data set from the total CSF data set, the total CSF data
set, and the HUPO plasma data set. (b) GO functional annotation
for signal transducer and receptor activity. (c) SignalP prediction
of proteins with signal peptides.
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proteome analysis. During CSF peptidome profiling, we found
peptides confirming the secretase-related intramembrane cleav-
age of APLP1 and a peptide (residues 39–81) originated from
the removal of the signal peptide (residues 1–38) and conver-
tase action at the dibasic site (residues 82–83). The identified
protein sequence covers the region between the convertase
cleavage site (82–83) and the near-membrane region of the
protein (Figure 10a). The near-membrane secretase cleavage
is the probable cause of APLP1’s launch into extracellular space.
2. Xylosyltransferase I (XT-I) catalyzes transfer of xylose from
UDP-xylose to serine residues in proteoglycan core proteins
and is a regulatory factor in chondroitin sulfate synthesis.75 XT-I
is a type II membrane protein with a short N-terminal part
(residues 1–17) facing the cytoplasm, signal anchor (residues
18–38), and C-terminal part (residues 39–959) in the luminal
part of the rough endoplasmic reticulum. Secretion of XT-I into
the extracellular space has already been shown.76 XT-I was
proposed as a synovial fluid marker of cartilage destruction77
and, more recently, as a serum marker in systemic sclerosis.78
We identified XT-I during the CSF proteome mapping experi-
ment. Additionally, peptides originating from the signal-anchor
membrane part of XT-I were also identified in the CSF
peptidome (Figure 10b). These peptides carry the intramem-
brane secretase-like cleavage signature at their N-termini and
Figure 10. Interplay of proteome and peptidome data. (a) Sequence coverage of amyloid precursor-like protein 1; (b) xylosyltransferase
I; (c) integral membrane protein 2B. Sequence areas identified during the CSF proteomemapping experiment are shown in red. Sequence
areas identified during the CSF peptidome profiling are shown in blue.
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dibasic cleavage signature at their C-termini. It is likely that
with the signal anchor cut the C-terminal part of the protein
is released into extracellular space.
3. Integral membrane protein 2B (ITM2B also known as
BRI2 or E25B) is a type II integral membrane protein that
belongs to a family including two other members, ITM2A (BRI1
or E25A) and ITM2C (BRI3 or E25C). The extracellular part of
BRI2 is known to be proteolytically processed by convertases
resulting in the release of a 23-amino-acid C-terminal fragment
of unknown function (CTF23).79 Mutations in the ITM2B gene
are associated with familial British and Danish forms of
dementia.80,81 ITM2B interacts with amyloid precursor protein
(APP) and has a modulatory effect on APP processing, increas-
ing the levels of cellular APP as well as its γ-secretase-generated
C-terminal fragments.82 The extracellular part of ITM2B was
identified during the CSF proteome profiling. CTF-23 and CTF-
23-derived peptides were identified during CSF peptidome
mapping (Figure 10c). Additionally, the 18-amino-acid peptide
YIKDDVILNEPSADAPAA derived from the membrane proximal
region was also identified. It is possible that the production of
this peptide leads to the release of the extracellular part of
ITM2B.
Overrepresentation of Transmembrane Receptor Protein
Tyrosine Phosphatases. We used the BinGO tool27 to find
statistically over-represented GO terms in our CSF proteome
data set in comparison to the GO annotations of the whole
human proteome (Figure 11). In addition to the significant
enrichment of basic CSF functions related to host defense and
intrinsic neurological regulation, the transmembrane receptor
protein tyrosine phosphatase (PTPR) term was also significantly
augmented (p ) 1.95 × 10-7). The functional meaning of this
PTPR enrichment is unknown; however, proteome and pepti-
dome profiling data shed some light on the mechanisms
leading to the presence of these proteins in CSF as will be
discussed below.
Protein tyrosine phosphatase receptor type Z (PTPRZ) is a
member of the PTPR subgroup of the protein phosphatase
family. Even though tyrosine phosphatases are known to be
signaling molecules that regulate a variety of developmental
and functional processes in the CNS, the intracellular mech-
anisms by which they regulate cellular signaling pathways are
not well understood.83 PTPRZ is specifically expressed in the
central nervous system. It is a single-pass type I membrane pro-
tein with two cytoplasmic tyrosine-protein phosphatase domains
and an R-carbonic anhydrase and a fibronectin type III
extracellular domain. The protein sequence includes a 24-
amino-acid signal peptide at the N-terminus, a large extracel-
lular part (residues 25–1635), a 26-amino-acid membrane part
(residues 1636–1661), and a 653-amino-acid C-terminal cyto-
plasmic part (residues 1662–2314). It has been reported that
PTPRZ plays a critical role in functional recovery from demy-
elinating lesions in multiple sclerosis.84 Additionally, it has been
suggested that PTPRZ may regulate glioblastoma cell motil-
ity.85 We identified the extracellular part of PTPRZ during a
CSF proteome mapping experiment and peptides originating
from the membrane part of PTPRZ during CSF peptidome
mapping (Supporting Information Figure 4). These peptides
carry the intramembrane secretase-like cleavage signature at
their C-termini. It is likely that with the membrane part of
PTPRZ cut its extracellular part is released into extracellular
space. Taking into account the specific expression of PTPRZ
in remyelinating oligodendrocytes in multiple sclerosis lesions,
it is tempting to suggest that the soluble form of PTPRZ and/
or the peptides originated from the PTPRZ secretase-like
cleavage could be used as potential markers in multiple
sclerosis.
The extracellular parts of other PTPRs were also identified
in our CSF proteome mapping experiment. These include Islet
antigen-2 (IA-2 or PTPR-like N protein), an enzymatically
inactive PTPR located in neuroendocrine cells throughout the
body, which is a major autoantigen in type 1 diabetes86
(Supporting Information Figure 2a). Receptor tyrosine phos-
phatase δ, another example, is thought to be a neurite-
promoting homophilic adhesion molecule87 (Supporting In-
formation Figure 2b). Even though the corresponding peptides
carrying the intramembrane cleavage signature were identified
only for PTPRZ, we suggest that the mechanisms responsible
for release of the extracellular parts of the other PTPR group
members are similar to that proposed for PTPRZ.
Bioinformatics analysis of the CSF proteome furthermore
identified a large number of protein peptidases. In total, 42
hydrolases (EC 3.4) including 6 carboxypeptidases, 3 conver-
tases, and 5 aminopeptidases were detected. The occurrence
of these enzymes in the CSF samples hints at their potential
involvement in post-translational truncations of CSF proteins.
However, as is the case for all the enzymes discussed here, it
remains to be determined whether they and their associated
peptides are mere byproducts of the process of remodeling and
rearranging the cell surface or whether they play specific
functional roles in the mostly unexplored CSF universe.
Conclusions
We believe that the presented data set contains valuable
unique information which will enable interested researchers
to identify novel CNS regulatory mechanisms. Our study
demonstrates that MS-based technology has already advanced
sufficiently to allow not only detection of large numbers of
proteins of different abundance in biological fluids but also
identification of their endogenously processed peptides. Thus,
MS can now be used to study these processing events resulting
in cleavage or changing of the cleavage pattern which may
allow linking them to specific physiological or pathophysiologi-
cal events. Our data suggest that the major contributors to the
protein population of CSF are protein secretion combined with
ongoing proteolytic processes involved in cell surface remodel-
ing, protein shedding, and creation of regulatory peptides. The
CSF protein population differs in composition from that of
Figure 11. Statistically over-represented GO terms in our CSF
proteome data set as compared to annotations for the entire
human proteome.
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plasma presumably due to inherent CSF functions of an as yet
mostly unexplored nature.
The identification of 563 peptide forms and 798 proteins in
our CSF profiling study offers a library to the community
working on cerebrospinal fluid and endocrine signaling. To
enable unhindered and open access to our data, we made them
available at the Max-Planck Unified Proteome database
(MAPU).88 With time and further research, we expect the
cerebrospinal fluid to be an important source of novel regula-
tory peptides and biological markers.
Abbreviations: ABC, ammonium bicarbonate; ACTH, adreno-
corticotropic hormone; CNS, central nervous system; APLP1,
amyloid precursor-like protein 1; APLP2, amyloid precursor-
like protein 2; APP, -amyloid precursor protein; BiNGO,
Biological Networks Gene Ontology; CE, collision energy; CSF,
cerebrospinal fluid; FT-ICR, Fourier transform ion cyclotron
resonance; FTMS, Fourier transform mass spectrometry;
GeLC-MS, gel enhanced liquid chromatography–mass spec-
trometry; GO, Gene Ontology; GPCR, G protein-coupled recep-
tor; HB-EGF, Heparin-binding EGF-like growth factor; HCD,
higher-energy C-trap dissociation; HPPP, Human Plasma Pro-
teome Project; HUPO, Human Proteome Organization; IGF-2,
insulin-like growth factor-2; ITM2B, integral membrane protein
2B; JP, joining peptide of POMC; LC-MS/MS, liquid chroma-
tography-tandem mass spectrometry; LTQ-FT, linear quadru-
pole ion trap-Fourier transform mass spectrometer; MS, mass
spectrometry; MS/MS, tandem mass spectrometry; MS3, MS/
MS/MS; POMC, pro-opiomelanocortin; PTPR, protein tyrosine
phosphatase receptor; PTPRZ, protein tyrosine phosphatase
receptor type ; SDS-PAGE, sodium dodecyl sulfate-polyacry-
lamide gel electrophoresis; SIM, selected ion monitoring;
STAGE, stop and go extraction; TFA, trifluoroacetic acid; XT-I,
xylosyltransferase I.
Supporting Information Available: CSF peptides
identified by high-accuracy mass spectrometry in both MS and
MS/MS modes (Supplementary Table 1). Unique peptide
precursors identified solely during CSF peptidome profiling
(Supplementary Table 2). Identified CSF peptides derived by
convertase cleavage (Supplementary Table 3). Identified CSF
peptides derived by secretase cleavage (Supplementary Table
4). CSF protiens identified by high-accuracy mass spectrometry
(Supplementary Table 5). CSF proteome GO categorization
(Supplementary Figure 1). Sequence coverage of PTPR-like N
and PTPR-delta at the proteome level (Supplementary Figure 2).
Comparision of CSF proteome with Human Plasma Proteome
(Supplementary Figure 3). Sequence coverage of receptor
tyrosine phosphatase zeta at the proteome and peptidome level
(Supplementary Figure 4). This material is available free of
charge via the Internet at http://pubs.acs.org.
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Supplementary Figure 2  
 
Sequence coverage of PTPR-like N and PTPR–delta at the proteome level. Sequences 
identified during the CSF proteome mapping are shown in red. 
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Supplementary Figure 3 
 
 
Comparison of CSF proteome with Human Plasma Proteome 
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Supplementary Figure 4 
 
Sequence coverage of receptor tyrosine phosphatase zeta at the proteome and 
peptidome level. Sequences identified during the CSF proteome mapping are shown 
in red. The sequence identified during the CSF peptidome profiling is shown in blue. 
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Future directions 
 
Neuropeptides are key signaling molecules in the synapses and represent a major part of the 
ligands of G protein-coupled receptors (GPCRs), the main targets of contemporary 
pharmaceuticals (83). About one hundred and twenty of non-sensory receptors identified as 
GPCRs from the Human Genome Project have no known endogenous interactors. In addition to 
that, little is known about the other, non-GPCR-type novel transmembrane receptors with names 
such as “KIAA…”, “FAM…” or “Predicted…” Clearly identifying a cell surface target of the 
known endogenous ligand is easier than identifying an endogenous ligand for the transmembrane 
receptor.  The latest developments in capillary separation science and improvements in 
sensitivity and accuracy of mass spectrometers have provided us with unique opportunities to 
probe the neuropeptidome to great depths and to identify novel low abundant neuropeptides (54, 
69). Neuropeptides are harbored in synaptosomal vesicles. Synaptosomes are artificial 
membranous structures containing the components of nerve synapses created during the process 
of brain tissue homogenization (84). I believe that a simple enrichment of synaptosomal fraction 
with the following lysis of the synaptosomes to release the neuropeptides could significantly 
improve the sensitivity of the neuropeptidome profiling compared to the profiling of whole brain 
tissue homogenate. As a continuation of the neuropeptidome investigation, I already performed 
analysis of the rat brain synaptosomal neuropeptides by nanoLC-MS and discovered a number of 
novel neuropeptides. One of my goals is to characterize interactors/targets of some of the 
identified novel neuropeptides - I think that the outcome could be beneficial for our 
understanding of basic physiological and pathophysiological mechanisms and, potentially, lead 
to novel therapies. 
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Outlook 
 
There is no doubt that further developments in high accuracy and high resolution mass 
spectrometry instrumentation will provide scientists with even faster and accurate discovery 
tools. At this moment the LTQ-Orbitrap justifiably dominates the proteomics market and it 
seems there is no viable competition for this unique instrument. Nevertheless, one cannot 
exclude, for example, that the ongoing evolution of the TOF instrumentation possibly will lead to 
creation of a new highly accurate mass spectrometer, e.g. an LTQ-TOF, which due to its nature 
should operate faster than the LTQ-Orbitrap and could provide similar mass accuracy and 
resolution. Then, perhaps, the time will come when proteomes are confidently characterized by 
utilizing highly accurate data at both MS and MS/MS levels. Much needed developments in the 
area of protein identification and characterization software will undoubtedly facilitate data 
analysis and, potentially, completely eliminate manual data analysis. Advances in sample 
preparation and capillary separation technologies will definitely increase the overall sensitivity 
of the LC-MS instrumentation. Hopefully, biologists will start to routinely use this powerful 
proteomics tool-box, which certainly will result in many exciting discoveries. 
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